New aspects of tissue mast cells in inflammatory airway diseases

Andersson, Cecilia

2011

Link to publication

Citation for published version (APA):
New Aspects of Tissue Mast Cells in Inflammatory Airway Diseases

Cecilia Andersson

Respiratory Medicine & Allergology
Department of Clinical Sciences
Lund University
New Aspects of Tissue Mast Cells in Inflammatory Airway Diseases

Cecilia Andersson

AKADEMISK AVHANDLING

som för avläggande av doktorsexamen i medicinsk vetenskap
vid Medicinska Fakulteten, Lunds universitet,
kommer att offentligen försvaras i Belfragesalen BMC D15, Lund,
fredagen den 11 februari 2011, kl. 9.00.

Fakultetsopponent:
Prof essor Sally Wenzel
University of Pittsburgh
**Organization**  
LUND UNIVERSITY  
Department of Clinical Sciences, Lund  
Department of Experimental Medical Sciences

**Document name**  
DOCTORAL DISSERTATION

**Date of issue**  
2011-01-02

**Sponsoring organization**

**Author(s)**  
Cecilia Azdersson

**Title and subtitle**  
New Aspects of Tissue Mast Cells in Inflammatory Airway Diseases

**Abstract**

Mast cells are found throughout the body, but are especially prominent in tissues that have direct contact with the external milieu such as the skin, gastrointestinal tract and lungs. Mast cells are commonly recognized for their detrimental role in allergic reactions and can, upon activation through the high-affinity receptor for IgE (FcεRI), rapidly produce and secrete many of the mediators responsible for the typical symptoms in urticaria, asthma and rhinitis. However, increasing amounts of data show that mast cells have important, even vital, roles in host defence against bacteria, viruses, parasites and venom.

Mast cells exist as two different subtypes, MCT (mucosal mast cells) and MCTC (connective tissue mast cells). These two subtypes differ in their molecular expression and distribution in the body. MCT are for example the dominating subtype in the lungs, while MCTC are most common in the skin and the gastrointestinal tract. Since mast cells (unlike the majority of other immune cells) only mature inside the tissue, their final phenotype is highly dependent on the local tissue milieu. This gives rise to pronounced heterogeneity within the populations. The mast cell populations differ between human and rodents. In this thesis mast cells were, henceforth, studied in human tissue from patients suffering from allergic and non-allergic inflammatory airway diseases. A variety of histochemical methods are used to study the balance between MCT and MCTC, mast cell morphology and mediator and receptor expression patterns in different lung compartments.

Under healthy baseline conditions, mast cells were abundant at all airway levels with a gradually increasing numbers towards the alveolar parenchyma. The MCT and MCTC populations could be further divided into site-specific subpopulations with regard to expression of mediators and morphology. A main finding was that the alveolar mast cell population had low expression of FcεRI in the healthy human lung. In COPD, CF and IPF, a significant increase in the proportion and density of MCTC with increased expression of CD88, IL-6 and TGF-β were found. Several mast cell alterations correlated to patient lung function and to the degree of remodelling compared to healthy controls. Mast cell numbers did not differ in healthy controls, patients with mild asthma or rhinitis with or without bronchial hyperreactivity. In patients with uncontrolled asthma despite treatment with inhaled corticosteroids, an increase of MCTC was found in the bronchi and alveolar parenchyma. In mild and uncontrolled asthma a significant increase of the expression of FcεRI was found in the alveolar parenchyma.

In conclusion, the prevailing MCT and MCTC populations could be further divided into site-specific subpopulations dependent on the local microenvironment already at healthy conditions. Mast cell alterations are present in patients with COPD, CF and IPF, diseases characterised by increases in the density of MCTC with increased expression of pro-inflammatory and pro-fibrotic molecules. Uncontrolled atopic asthma patients have expanded MCT and MCTC populations in the alveolar parenchyma. The increase in alveolar mast cell expression of FcεRI might be specific to atopic asthma since we could detect similar changes in mild asthma, but not in patients with allergic rhinitis, CF and COPD.

**Key words:** Mast cell, heterogeneity, inflammation, lung, tissue, alveolar parenchyma, high-affinity receptor for IgE, asthma, rhinitis, chronic obstructive pulmonary disease, cystic fibrosis, idiopathic pulmonary fibrosis.

**Classification system and/or index terms (if any):**

**Supplementary bibliographical information:**

<table>
<thead>
<tr>
<th>Language</th>
<th>ISBN</th>
</tr>
</thead>
<tbody>
<tr>
<td>English</td>
<td>978-91-86671-60-0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSN and key title.</th>
<th>Number of pages</th>
<th>Security classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1652-8220</td>
<td>188</td>
<td></td>
</tr>
</tbody>
</table>

**Distribution by (name and address):**  
I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation.

**Signature**  
[Signature]

**Date**  
2011-01-02
New Aspects of Tissue Mast Cells in Inflammatory Airway Diseases

Doctoral Thesis

by

Cecilia Andersson

Lund University
Faculty of Medicine

Department of Respiratory Medicine and Allergology
Unit of Airway Inflammation
Clinical Sciences, Lund
2011
Cover image: High magnification (600x) micrograph of lung tissue double stained for mast cell sub-populations: MC\textsubscript{T} (red) and MC\textsubscript{TC} (brown).
Till Mamma och Pappa
för er villkorslösa kärlek
Dum Spiro Spero

Så länge jag andas, hoppas jag
While I breathe, I hope

Cicero
# Contents

List of Papers 11

Additional peer-reviewed papers, not included in the thesis 12

Abbreviations 13

**Introduction** 15

- Inflammatory Airway Diseases 15
- Monitoring Airway Inflammation 23
- The Mast Cell 25

**Aims and Hypotheses** 33

**Methodology** 35

- Subjects and Patient Characterisation 35
- Tissue Acquisition and Processing 37
- Histology and Immunohistochemistry 39
- Measurements 41

**Results** 45

- Novel Site-Specific Mast Cell Subpopulations in the Human Lung (Paper I) 45
- Marked Alterations of Lung Mast Cell Populations in Patients with COPD (Paper II) 46
- Activated Connective Tissue Mast Cells Infiltrate Diseased Lung Areas in Cystic Fibrosis and Idiopathic Pulmonary Fibrosis (Paper III) 49
- Mast cell-Associated Alveolar Inflammation in Patients with Atopic Uncontrolled Asthma (Paper IV) 50
- Alveolar Mast Cell Expression of FcεRI Differs between Allergic Asthma and Rhinitis (Paper V) 52

**Discussion** 55

**Conclusions and Summary** 61

**Future Perspective** 63

Populärvetenskaplig sammanfattning på svenska 65

Acknowledgements 67

References 69
This thesis is based on the following papers, which will be referred to in the text by their Roman numerals.


Papers are reproduced with permission from the publisher
Additional peer-reviewed papers, not included in the thesis


Abbreviations

ACT  asthma control test
AP  alkaline phosphatase
AR  allergic rhinitis
CF  cystic fibrosis
COPD  chronic obstructive pulmonary disease
DAB  3,3’ diaminobenzidine
FcεRI  high affinity receptor for IgE
FEV₁  forced expiratory volume in 1 second
FVC  forced vital capacity
GINA  global initiative for asthma
GOLD  global initiative for chronic obstructive lung disease
HRP  horseradish peroxidase
ICS  inhaled glucocorticosteroids
IOS  impulse oscillometry
IgE  immunoglobulin E
IPF  idiopathic pulmonary fibrosis
MCₜ  tryptase positive mast cells (mucosal mast cells)
MCₜₐ  tryptase and chymase positive mast cells (connective tissue mast cells)
NO  nitric oxide
PD₂₀  cumulative dose of bronchoconstrictor where FEV₁ fell by 20% or more
PEF  peak expiratory flow
p.r.n  pro re nata, as needed
RV  residual volume
SCF  stem cell factor
TLR  toll-like receptor
Introduction

Inflammatory Airway Diseases

The respiratory tract has an estimated surface area of 70 m$^2$ that is in direct contact with the external milieu: from the mucosal tissue in the conducting airways to the alveoli in the peripheral lung parenchyma. The main function of the lung is to maintain gas exchange and thus host survival. This, however, leads to increased risk of exposing the host to various harmful agents. As defence, each lung compartment has its specific population of immune cells that participate in inflammatory responses. The distinct cell populations are a reflection of the diverse properties of local tissue and of different deposition of pathogens, toxins and allergens throughout the lung.

Airway inflammation is initiated by stimuli at the epithelial surface and cells already present in the tissue mediate the acute inflammation. The stimuli cause activation of resident leucocytes and structural cells to produce various cytokines, chemokines and growth factors that cause inflammatory symptoms. Vasodilation and increased blood flow causes redness (rubor) and increased heat (calor). Increased blood vessel permeability results in exudation of fluid and plasma proteins into the tissue, which causes oedema (tumor) and some of the released mediators increase the sensitivity to pain (dolor). Released mediators cause migration of leukocytes into the tissue and act in parallel with other factors, such as the complement system, fibrin cascades and immunoglobulins in the inflammatory response$^1$.

The cellular inflammatory responses involve increased endothelial expression of adhesion molecules and transmigration of cells (monocytes/macrophages, T-lymphocytes, neutrophils, eosinophils and B-lymphocytes) into the extravascular space$^2$. In the tissue, immune cells secrete factors that stimulate extracellular matrix production$^3$. Resolution of the chronic inflammatory response is an active process that involves elimination of harmful agents (phagocytosis), removal of leucocytes (necrosis, apoptosis and luminal entry), and termination of wound healing. A persistent chronic inflammation might lead to formation of fibrosis and to the development of autoimmune diseases$^1$. Lung diseases characterised by chronic inflammation affect a substantial part of the human population. Some of the most common are asthma, chronic obstructive pulmonary diseases (COPD) and cystic fibrosis (CF).
Allergic Airway Diseases

Asthma

Approximately 300 million people are currently suffering from asthma, and asthma causes almost 300,000 deaths globally each year. Asthma is the most common chronic disease among children, and one of the strongest determinants is parental history of asthma and atopy. Airflow obstruction, inflammation and bronchial hyperresponsiveness induced by a variety of exogenous and endogenous stimuli are hallmarks of the disease, although asthma is considered to be a heterogeneous disease. International committees have been formed with the goal to produce recommendations for the management, diagnosis and awareness of asthma (Global Initiative for Asthma – GINA). Today, asthma is divided into different categories based on phenotypic characteristics:

- **Clinical and physiological phenotypes:** severity, exacerbation frequency, resistance to treatment, age onset e.g.

- **Phenotype related to triggers:** drugs, environmental allergens, occupational allergens, exercise e.g.

- **Inflammatory phenotypes:** eosinophilic, neutrophilic or pauci-granulocytic

Asthma is traditionally considered to be a large airway disease (Figure 1), characterised by an increase in density of inflammatory cells (eosinophils, CD4+ T-lymphocytes, macrophages and mast cells) in the submucosa and adventitia of the bronchial wall, which produce Th2 cytokines (IL-3, IL-4, IL-5, IL-9, IL-13 and GM-CSF). In more severe forms of asthma, CD8+ T-lymphocytes and neutrophils infiltrate the tissue. Damage to the airway epithelium in the asthmatic lung results in thickening of the true basement membrane. This is due to proliferation of myofibroblasts that produce collagen, laminin and tenascin. The epithelium undergoes damage-repair processes with metaplasia and increased number of goblet cells as a consequence. Increase in deposition of extra cellular matrix and hyperplasia of vessels, neurons and smooth muscle are typical pathological features of asthma.

Not only the central airways, but also small airways are involved in the inflammatory response in the asthmatic lung. Inflammation in the small airways has, however, remained largely unexamined because of the relative inaccessibility of these structures. Most of the information of tissue inflammation in small airways comes from autopsy studies of fatal asthma. Due to the possibility of obtaining transbronchial biopsies under more controlled conditions, it has been shown that the inflammation evident in the large airways, occurs in the distal airways as well. In large and small airways, the number of lymphocytes and eosinophils were found to be increased in asthmatics compared to healthy controls. Structural changes and remodelling, similar to that seen in large airways seem to be present also in the small airways. Furthermore, Balzar et al. showed that inflammatory cell density even seems to be increased towards the periphery of the airway.
Inflammation in the alveolar parenchyma has been shown in different asthma phenotypes\textsuperscript{14-16}. Kraft \textit{et al.}\textsuperscript{16}, found an increase in alveolar parenchymal eosinophil numbers in patients with nocturnal asthma compared to patients with non-nocturnal asthma, and this increase correlated to the night time fall in FEV\textsubscript{1}. However, much is still unknown regarding the involvement of peripheral lung inflammation in asthma.

Treatment of asthma patients with inhaled $\beta_2$ agonists (short- and long-acting), that cause smooth muscle relaxation is common. By the introduction of inhaled glucocorticosteroids (ICS), due to their broad anti-inflammatory effect, an improvement for many, but not all, asthma and rhinitis patients are achieved\textsuperscript{7,17}. Anti-IgE therapy has been shown to down-regulate both IgE and Fc$\varepsilon$RI-bearing cells in asthmatic bronchi\textsuperscript{18,19}.

\textbf{Rhinitis}

The term rhinitis refers to an inflammatory disease of the nasal mucosa. Rhinitis is classified as seasonal allergic rhinitis (AR, hay fever), perennial AR and perennial non-allergic rhinitis (vasomotor rhinitis). In the studies included in the present thesis the rhinitis patients are characterised as seasonal AR and perennial AR. In hay fever and perennial AR the inflammation is induced by allergen stimulated, IgE-mediated, mast cell release of mediators like histamine, leukotrienes, prostaglandins and kinines. Increased numbers of eosinophils are seen in the mucosa of patients with hay fever and perennial AR. In clinical practice, diagnosis is based on the presence of secretion, itching, sneezing and blockage. Sneezing is considered to be induced by mediator stimulation of sensory nerve endings in the mucosa and hyper-secretion from nasal glands has been proposed to be mediated via a parasympathic reflex. The nasal blockage seems to be mediated via an effect of mediators on blood vessels causing both edema and increased blood accumulation in the mucosa\textsuperscript{20-22}.

Most atopic asthmatics have concurrent AR whereas clinical manifestation of asthma in rhinitis patients is more rare\textsuperscript{23}. Reports show that AR patients often present symptoms such as unspecific bronchial hyper responsiveness (BHR), shortness of breath, wheezing and cough, all typical symptoms in asthma\textsuperscript{24}. The similarities in induction and development of inflammation in the nasal and bronchial mucosa have lead to ongoing discussions suggesting that allergic asthma and AR appear to be organ specific variants of the same disease with a gradual development of respiratory allergy from the upper airways (rhinitis) towards involvement of the lower airways (asthma)\textsuperscript{25}. In allergen-induced inflammation in AR and asthma the same inflammatory cells (eosinophils, CD4+ T-lymphocytes and mast cells) and mechanisms appears to be present\textsuperscript{26-29}. Much is, however, unknown regarding the relevance of distal lung inflammation and its possible involvement in the transition of rhinitis into asthma.

As histamine and leukotrienes have been shown to play important roles in the pathology of allergic rhinitis, treatment with anti-histamines ($H_1$-blockers) and leukotriene-antagonists is commonly used. Sodium cromoglycate, described as a “mast cell stabilizer”, and treatment with intranasal glucocorticosteroids has been proven useful\textsuperscript{17}.
Chronic Obstructive Pulmonary Disease (COPD)

According to WHO, 80 million people are suffering of moderate to severe COPD, and more than 3 million people died as a consequence of COPD in 2005. This corresponds to 5% of all deaths globally, and estimates show that by 2020, COPD will be the third leading cause of death worldwide. The major risk factor for developing COPD is cigarette smoking, although only approximately 15% of all smokers develop the disease. COPD is characterised by an irreversible and progressive airflow limitation combined with non-pulmonary conditions (lung cancer, skeletal muscle dysfunction, osteoporosis and cardiac/vascular disease) that contribute to the mortality of the disease. The Global initiative for chronic Obstructive Lung Disease (GOLD) was formed to improve prevention and management of COPD, as well as to increase the awareness of the disease. The diagnosis of COPD is confirmed by spirometry, and the presence of a postbronchodilator FEV₁ < 80% of the predicted value in combination with a FEV₁/FVC < 70% confirms airflow limitations that is not fully reversible. A classification of COPD severity into 4 stages is commonly applied (GOLD I-IV). COPD, in contrast to asthma, is considered to be a peripheral airway disease, although the chronic inflammation is present in the whole lung, from the bronchi (central airways) and bronchioles (small airways) to the alveolar parenchyma (Figure 2C, D). Additionally, the pulmonary circulation gets affected as the disease progresses in severity. The increased airway resistance observed in COPD is ascribed to two major pathological features: small airway abnormalities and parenchymal destructions (emphysema). The main histopathological changes found in small airways are: increased number of goblet cells in the airway epithelium, increased occurrence of mucus plugging in the airway lumen, increased number of lymphoid follicles and enlarged smooth muscle mass and fibrosis formation in and around the small airway wall. The inflammatory infiltrate in the small airway wall is characterised by elevated number of T-lymphocytes (in particular CD8+ cells, in contrast to CD4+ cells in asthma), neutrophils, macrophages and B-lymphocytes. The other hallmark of COPD, emphysema, is defined as a permanent destruction of the alveolar septa that causes enlargement of airspaces and entailed imbalance in the gas-exchange. These lesions lead to decreased elastic recoil of the lung and, to some extent, collapse of the small airways and terminal bronchioles. Scattered areas of fibrosis can also occur in the COPD affected alveolar parenchyma. The inflammatory response in COPD is caused by inhalation of cigarette smoke (or other noxious particles) that activates the airway epithelium and alveolar macrophages to secrete cytokines like IL-8, LTB₄ and TNF-α. Many of these mediators are important in the innate immunity and cause neutrophil recruitment. Exposure to tobacco increases the oxidative metabolism in macrophages and can direct destroy epithelial integrity.
There are two major mechanisms proposed for the cause of tissue damage in COPD: protease-antiprotease imbalance and oxidant-antioxidant imbalance. Recruited neutrophils release proteolytic enzymes like elastase, cathepsin G and matrix metalloproteases (MMPs). The oxidative effect of cigarette smoke impairs the body’s normal anti-protease activity (e.g. \( \alpha_1 \)-antitrypsin), which usually should neutralise the released proteases. The activity of the proteases causes destruction of the alveolar walls and release of IL-8 and TGF-\( \beta \) from airway proteoglycans, further enhancing neutrophil recruitment and collagen deposition\(^7\).

Today, no effective treatment of COPD exists. The most effective way of preventing the progression of the disease is to stop smoking. The current therapy used, is mainly long acting \( \beta_2 \) agonists and anti-cholinergic drugs (decreased air trapping). ICS (suppression of the inflammatory response) is a common therapy, although COPD is considered to be steroid-resistant\(^7\). The main focus for future therapy should be to target peripheral inflammation, which is poorly assessed by today’s therapy.

**Cystic Fibrosis**

Cystic fibrosis (CF) is one of the most common hereditary (autosomal recessive) diseases in Europe and the United States and affects approximately 1 in 3000 births. In 1959 the mean age of survival of a child born with CF was 6 months, today the mean life expectancy has increased to 38 years. CF is caused by a mutation, the most common is a deletion (\( \Delta F 508 \)) in the gene for the protein CFTR (Cystic Fibrosis Transmembrane conductance Regulator) located in a chloride channel expressed by e.g. epithelial cells. The mutation causes dehydrated and hyperviscous secretion that leads
to mucus plugging, impaired mucociliary clearance and airway obstruction. The conse-
quency is airway infections by pathogens such as Staphylococcus aureus, Haemophilus
influenzae and Pseudomonas aeruginosa, which induce chronic inflammation and in the
end, respiratory failure\textsuperscript{41 42 43 44}.

The damaged airway epithelium in CF secretes IL-8, which attracts neutrophils into
the lung. Once there, neutrophils trigger the release of proinflammatory mediators
and chemotactants, which maintain the inflammatory response. Mediators such as
IL-6, TNF-\(\alpha\), and LTB\(_4\), are found to be elevated in CF and cause recruitment of
other inflammatory cells, such as macrophages. Cytokines from macrophages in turn
mediates further neutrophil attraction. Upon activation, neutrophils release proteases
(e.g. MMP9 and elastase) important in the defence against pathogens. However, the
release of large amounts of these mediators during neutrophil activation, phagocytosis
and apoptosis cause airway destruction, bronchiectasis and formation of fibrotic lesions
(Figure 2E, F). The CF airway is exposed to oxygen radicals derived not only from
environmental oxygen and bacterial products, but also from the strong host response.
Furthermore, toll like receptors (TLRs), which recognise pathogen and inflammatory
products, mediate the inflammation\textsuperscript{45-48}.

Given that chronic bacterial infections lead to chronic inflammation, CF patients
are commonly treated with antibiotics. Inhaled and oral glucocorticosteroids and anti-
inflammatory drugs are given with the aim to suppress the inflammatory response,
although only modest effects are observed\textsuperscript{45 49}. Chest physiotherapy is commonly used
to improve airway clearance. Today, there is no effective treatment of the disease and in
severe cases the patient is in need of lung transplantation.

**Idiopathic Pulmonary Fibrosis**

Generally, acute injury to the lung is followed by an inflammatory response with infil-
tration of inflammatory cells and release of mediators that eliminate the harmful agents.
Normally the inflammation is resolved and the damaged tissue repaired by processes
like apoptosis and phagocytosis of immune cells, healing and regeneration of the tis-
ssue through actions of structural cells. Fibrosis results from chronic inflammation, in
which persistent stimuli such as infectious agents, chemicals, toxins or radiation, cause
inflammation, tissue remodelling and repair processes to occur simultaneously. In this
uncontrolled wound healing response, in which important checkpoints for regulation
of the response is lost, a milieu rich in various cytokines, chemokines, growth factors
and tissue destructive enzymes causes accumulation of extra cellular matrix proteins
and formation of fibrotic lesions\textsuperscript{1}.

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with
unknown cause. IPF affects approximately 5 million people worldwide and is more
common in men than women (ratio 1.4:1.0). The majority of patients are over 50 years
old and the mean age of survival after diagnosis is 4 years. Diagnosis is set with regard to
high-resolution computed tomography (HRCT; peripheral opacity, honeycombing and
bronchiectasis), lung function values (decreased FVC and FEV\(_1\)) and impaired gas ex-
change and oxygenation during exercise\textsuperscript{50-52}. Due to the unspecific pattern of leucocytes in BAL fluids, surgical lung biopsies are important for diagnosis of IPF. The histopathological abnormality associated with IPF is called \textit{usual interstitial pneumonia} (UIP) and is characterised by normal lung structures alternating with patchy areas of parenchymal fibrosis. The fibrotic lesions are defined by thickening of the alveolar septa in mildly affected areas to complete distortion of the parenchyma with connective tissue replacing normal lung tissue and occurrence of cystic structures (honeycombing) (Figure 2G, H). Another hallmark of the disease is manifestation of structures called fibroblast foci: loose extracellular matrix, scattered with fibroblast-like cells\textsuperscript{51 53 54}. Traditionally, IPF was thought to be caused by a primary injury that initiates an inflammatory response, resulting in formation of fibrosis\textsuperscript{55}. However, animal models have shown that pulmonary fibrosis can arise without inflammatory cells. Furthermore, anti-inflammatory and inflammatory-suppressive drugs do not seem to be effective in the treatment of the disease\textsuperscript{55}. New data have shown that a rapid (or even absent) inflammatory phase might precede the uncontrolled wound-healing response. Recent research has shown that damage epithelium might be an important source of fibrinogenic cytokines, such as TGF-\(\beta\), that increase fibroblast proliferation and migration and production of connective tissue proteins\textsuperscript{56}. These fibroblasts seem to be abnormally responsive to TGF-\(\beta\) and more resistant to apoptosis. For unknown reasons, the repair process never terminates and formation of fibrosis continues\textsuperscript{57 58}.

\section*{Airway Infections}

Pathogens are aggravating factors in the development of the obstructive airway diseases described above. Knowledge of how the host’s immune response to pathogens affects the susceptibility to develop chronic inflammatory airway diseases remains poorly understood. Longitudinal studies have shown that having a respiratory syncytial virus (RSV) infection as a child increases the risk of developing asthma later in life. Acute exacerbations are related to great health care costs, health status, quality of life and morbidity and are a feature of both asthma and COPD. In the majority of cases the exacerbations are caused by airway infections. Acute exacerbations are characterised by a decrease of the patient lung function compared to baseline values, shortness of breath and/or wheezing, cough and increased production of purulent sputum. Viral infections are thought to increase production of chemokines and cytokines from the airway epithelium, initiating host defence and inflammatory responses\textsuperscript{59 60}. 
Figure 2. Trichrome stained sections of small airways (A, C, E, G; scale bar = 100µm) and alveolar parenchyma (B, D, F, H; scale bar = 200µm) from healthy controls (A, B), patients with COPD (C, D), CF (E, F) and IPF (G, H). Pictures A-F are stained with Masson’s trichrome and G-H with Gomori’s trichrome.
Monitoring Airway Inflammation

Pathological alterations are present throughout the human lung and several techniques for assessment of cellular, biochemical and molecular markers of inflammation are available. The technique used, should be selected depending on the aim of the study and evaluated for patient safety, reproducibility and repeatability.

**Spirometry**

The most widely used approach to study obstructive pulmonary diseases is through pulmonary function tests. Measurements of forced expiratory volume in 1 second (FEV$_1$), peak expiratory flow (PEF), forced vital capacity (FVC) and residual volume (RV) can show signs of air trapping and obstruction in both large and small airways. Difficulties with the mentioned lung function tests include weak correlations to the inflammatory status of the airways and poor representation of alterations in peripheral lung.

**Impulse Oscillometry**

In impulse oscillometry (IOS), pressure impulses are superimposed on the tidal breathing of the patient at different frequency and measure tissue resistance and reactance. Although not widely used, IOS is particularly useful since the resistance of peripheral airways can be calculated.

**Exhaled Nitric Oxide**

Exhaled nitric oxide (NO) is one of the most established biomarkers of airway inflammation and has for example been shown to correlate with eosinophilic activity in allergic patients. NO is thought to mainly be produced by epithelial cells in the central airways and by alveolar macrophages in the parenchyma. By measurements of exhaled NO concentrations at different flows, inflammation in central and distal airways can be assessed.

**Sputum**

Spontaneous or induced (by hypertonic saline) sputum samples are commonly collected and used for measurements of airway inflammation. Samples can be used for cell counts, immunohistochemical staining as well as for measurements of mediators. Analysis of sputum samples have been proven useful in both asthma and COPD since it can predict patient’s response to ICS, as high numbers of eosinophils in sputum are associated to a presumptive favourable response. Elevated eosinophil numbers are found in asthma and COPD patients prior to exacerbations, and early intervention
with therapy has decreased the number of exacerbations and hospitalizations in these groups of patients. Due to the safety of the procedure, induced sputum can be used in patients with severe lung disease\textsuperscript{65}. However, one disadvantage with the procedure is that sputum mainly reflects the inflammation in large airways. Samples also primarily reflect changes in cell populations that are prone to go into the airway lumen, which result in an underrepresentation of tissue-dwelling cells.

**Bronchoalveolar Lavage**

Bronchoalveolar lavage (BAL) is an invasive technique where sterile saline is injected and flushed throughout the lung and fluid is sampled in aliquots, reflecting different parts of the lung. Lung compartments that are difficult to reach (small airways and alveolar parenchyma) are assessed with this technique and cell counts and mediators can be measured, mostly reflecting features of the airway epithelium\textsuperscript{66}. As for sputum, tissue-dwelling cells are difficult to study by the use of this technique.

**Direct Analysis of Diseased Tissue**

Since not all cells are equally represented in luminal sampling, direct analysis of tissue is important when studying inflammatory airway disease. The first bronchoscopy was performed in 1897, and was then used to remove foreign bodies from the airways. Rigid bronchoscopy later became an important method for visual inspection of the airways. The first flexible bronchoscope was invented in 1966 and improved the procedure with regard to accessibility of more distal bronchi and patient comfort\textsuperscript{67 68}. However, until 30 years ago histological assessment of living patients under controlled circumstances was rare. Histological studies on asthma used autopsy tissue material from fatal cases but little was known regarding the inflammatory response in the airway wall in patients with milder disease\textsuperscript{69}. The development of techniques to obtain lung biopsies have made a great progress in this field. Tissue acquisition in connection with lung resections, lobectomies and transplantations are common ways of studying tissue inflammation in for example patients with COPD, CF and lung fibrosis. These techniques are also commonly used for obtaining control tissue\textsuperscript{70 71}. An advantage with the techniques is the possibility to get large tissue blocks from several regions of the lung (also from the peripheral part of the lung). One drawback is however, that the patients commonly have other diagnoses that are the primary cause of surgery, such as lung cancer. The possibility of obtaining transbronchial biopsies has improved studies on inflammatory and structural changes in the distal airways\textsuperscript{69}. However, biopsy procedures are invasive methods and can be associated with bleeding, increased risk of infections and pneumothorax. Sample size of biopsies is small and to avoid bias sampling due to the heterogeneity of the disease, several biopsies (from different lung regions) from numerous patients are needed. Tissue analyses have many advantages. Direct *in vivo* studies of structural changes and cell densities in the airway wall using immunohistochemical
methods, electron microscopy and in situ hybridisation are achievable. Furthermore, after processing of the tissue, cell cultures with measurements of cell activation, migration and mediator release can be performed.

The Mast Cell

The German scientist Paul Erlich discovered the mast cell in 1878, and until recent times, mast cell activation has been mainly associated with harmful effects in allergic responses\(^72\). Mast cells originate in the bone marrow as haematopoietic stem cells, but circulate in the blood as immature precursors. Mast cells mature first when recruited into the tissue and are therefore particularly dependent on the local tissue milieu for the development of their final phenotype\(^73\)\(^74\). They are located in normal tissue throughout the body, but are especially prominent in tissue that face the external environment, e.g. skin, lung and gastro-intestinal tract\(^75\)\(^77\). Consequently, mast cells are among the first cells that can react on various harmful agents and initiate an immune response, and are believed to have significant roles in host defence against pathogens, regulation of homeostasis and wound healing\(^78\). As an example of the essential role of the mast cell, the urochordate \textit{Ciona intestinalis}, which is regarded as an ancestor of vertebrates 550 million years ago, have a cell population that stain metachromatically with toluidine blue and by the use of electron microscopy analysis have been shown to resemble connective tissue mast cells. These cells can also release histamine and prostaglandins upon activation. Thus, mast cells evolved and participated in host defence long before the development of other cells in the adaptive immune system\(^79\). Humans deficient in mast cells are not known, which is another indication of a fundamental role. However, excessive numbers of mast cells and concomitant release of mediators give rise to harmful reactions, exemplified by mastocytosis\(^80\). Mast cells are long-lived cells, which can survive for month or even years. Furthermore, the persistent and rapid response to harmful stimuli is unique for the cell. They react within seconds with release of active mediators, and unlike other cells participating in the early innate immunity, such as neutrophils, mast cells are not destroyed in the process and within days new granules have been formed\(^81\).

Mast Cell Heterogeneity

In humans, mast cells are found throughout the entire respiratory system, from upper airways, to the bronchi, bronchioles and alveolar parenchyma in the lower airways\(^76\). Large differences in mast cell distribution are found between rodents and humans\(^72\). Rodents have mast cells in the bronchial airway wall, but unlike humans, lack mast cells in the small airways and alveolar parenchyma. Indeed, in humans, mast cell density increases from the central airways to the peripheral lung\(^32\)\(^76\). Since mast cells mature in the tissue, the local milieu is important in the development of their final pheno-
type. While mast cells share many characteristics, they do not represent a homogenous population. Based on anatomic location in rodents, mast cells were already in 1960’s divided into two subtypes: connective tissue mast cells (CTMC) and mucosal mast cells (MMC)\textsuperscript{72}. The CTMC and MMC differ not only in their tissue distribution, but also in morphology, granule content and function\textsuperscript{82}. The knowledge of human mast cell heterogeneity is more limited, although like in rodents, human mast cells display subpopulations that differ in protease content, distribution, mediator expression and granule ultrastructure\textsuperscript{72, 83-86}.

One distinct mast cell population in humans shows measurable levels of the proteases tryptase, chymase, cathepsin G and carboxypeptidase and are called MC\textsubscript{T\textring{}}C since they express both tryptase and chymase (Figure 3A). These cells largely correspond to the CTMC population in rodents. The other mast cell subpopulation contains only tryptase and is known as MC\textsubscript{T} (Figure 3A), and corresponds to the MMC in rodents\textsuperscript{72}. A few studies have reported a mast cell subpopulation only positive for chymase, though these cells seem extremely rare and only comprise 1 \% of all mast cells in the lung\textsuperscript{77}. To properly study mast cells, it is not only important to consider the density of total mast cells, but also the density of the two major subtypes. This can be achieved by immunohistochemical double staining for tryptase and chymase\textsuperscript{86} (Figure 3A). The two subtypes can also be separated using transmission electron microscopy, since only MC\textsubscript{T} cells display a scroll-like granule ultrastructure, and lattice or grating structures are found in MC\textsubscript{T\textring{}}C cells\textsuperscript{87, 88} (Figure 3B). Little is known regarding the plasticity of the subtypes, although reports have suggested that one subtype can change into the other\textsuperscript{89}. In the healthy human lung, the dominating subtype is the MC\textsubscript{T\textring{}}C, comprising approximately 90 \% of all mast cells\textsuperscript{72}. In humans the proportion of the two subtypes has been shown to change in pathological conditions\textsuperscript{14}, a phenomenon that is likely to have functional consequences in the immune system.

![Figure 3](image_url)

**Figure 3.** High-magnification micrograph (600x) of immunohistochemical double staining of MC\textsubscript{T} (red) and MC\textsubscript{T\textring{}}C (brown) (A). Transmission electron micrograph showing a non-degranulated mast cell (B). High-power images of intact granules (lattice/grating and scrolls) are shown as insets. Scale bars = 5\(\mu\)m (A) and 1\(\mu\)m (B).
Not only the density of mast cells have been shown to change in disease, but also the distribution (microlocalisation) of mast cells within the airway wall. An increased number of mast cells have been shown in the airway epithelium in asthmatics which is likely to be important for the epithelial function. Increased numbers of total and degranulated mast cells have been reported in the airway mucosal glands in patients with fatal and non-fatal asthma compared to non-asthmatic subjects. These densities correlated significantly to the degree of mucus obstruction in the airway. In the smooth muscle bundles of asthmatics, elevated numbers of mast cells of the MC	extsubscript{TC} subtype were reported. This correlated positively to the airway hyperreactivity. Other studies have shown that smooth muscle associated mast cells have increased expression of Th2 cytokines (IL-4 and IL-13) and show increased degranulation in both large and small airways. Bradding et al., reported mast cell heterogeneity, not only in protease composition, but also with respect to cytokine expression where IL-4 was expressed preferentially by the MC	extsubscript{TC}, and IL-5 and IL-6 by the MC	extsubscript{T} subtype. When considering these findings, mast cell heterogeneity is likely to go beyond the division into MC	extsubscript{T} and MC	extsubscript{TC} subsets, and to be of importance when considering the role of mast cells in health and disease.

**Origin and Maturation of Mast Cells**

Mast cells develop from the bone marrow as CD34+ c-kit+ (CD117: receptor for stem cell factor) stem cells, although very little is known regarding mast cell progenitors in humans. Mast cells do not complete their maturation in the bone marrow but mature in the tissue, influenced by the local tissue milieu. Therefore, unlike other immune cells, mature mast cells are not found in the circulation. Studies of murine mast cell progenitors in the blood have shown that the progenitors express c-kit and contain few cytoplasmic granules but lack the FcεRI. Mast cells, unlike other haematopoietic stem cells, continue to express c-kit also when they are mature cells. An explanation for this is the great plasticity of these cells, i.e. the ability to change phenotype depending on the local environment. The most important growth factor for mast cell development is stem cell factor (SCF) that bind c-kit on the mast cell surface. SCF promotes mast cell development and survival as well as adhesion to the extra cellular matrix and has been shown to enhance IgE-dependent mediator release. Cytokines, like IL-4 in humans, regulate the development of mast cell subtypes. IL-4 can work synergistically together with SCF to promote mast cell survival and proliferation, as well as direct mast cell cytokine release towards a Th2 response. Another cytokine that regulate mast cell function is IL-9, which is also named mast cell growth factor. Mast cell progenitors have recently been identified to express integrins, such as β7 and mast cell homing into the lung require expression of both α4β1 and α4β7 binding to VCAM-1 and MAdCAM-1 in the endothelium as well as expression of the α chemokine receptor.
Mast Cell Activation

**FcεRI**

The hallmark of an immediate hypersensitivity reaction is crosslinking of a multivalent allergen to IgE bound to the IgE receptor (FcεRI) on the mast cell surface (Figure 4). This causes activation of the mast cell through a signal transduction pathway that terminates in fusion and exocytosis of granules with preformed mediators (e.g. proteases, TNF-α, histamine), and de novo production of lipid mediators (eicosanoids, prostaglandins, leukotrienes) and various cytokines. Consequently, the result of IgE-mediated mast cell activation includes bronchoconstriction, plasma extravasation leading to tissue oedema, recruitment of leucocytes and persistent inflammation. These actions contribute to the pathogenesis of anaphylaxis, urticaria, angioedema and exacerbations of asthma

The FcεRI is highly expressed on the surface of mast cells (about 500,000 copies per cell), and the regulation of expression is dependent on the concentration of circulating IgE. IgE binds to the FcεRI with high affinity (dissociation constant $10^{-10}$ M) and the binding is highly specific (isotype specific and not inhibited by excess of other immunoglobulins). In vitro studies have shown that IgE have the ability to prevent mast cell apoptosis, and can induce mast cell release of cytokines without degranulation.

Besides the role in allergic reactions, other biological roles of FcεRI activation of mast cells are under investigation. IgE-deficient mice are shown to have delayed elimination of intestinal parasites as well as increased numbers of larvae in the skeletal muscles compared to wild type controls. Parasite infection is characterised by high numbers of CD4+ T-lymphocytes and Th2 cytokines (IL-4, IL-5, IL-9 and IL-13) and high concentrations of IgE in serum. Most of the IgE produced upon parasite infections is polyclonal and thereby not specific and, anaphylaxis seldom occurs in infected patients.

![Figure 4. Schematic illustration of different stimuli that cause mast cell activation, with degranulation or degranulation-independent release of mediators as a consequence.](image)
FcεRI independent activation

Mast cells can be activated by other immunoglobulins such as IgG through binding to FcγRs (Figure 4). This is likely to have implications not only in recognition of specific antigens in allergic reactions, but also in the recognition of bacteria and elimination of parasites (pathogen specific antibodies)\textsuperscript{81,107}. Bacterial superantigens, such as \textit{S. aureus} protein A, which bind certain antibodies can similarly activate mast cells, independent of antigen specificity\textsuperscript{108}.

Mast cells can also be activated directly by viruses and bacteria through their expression of toll-like receptors (TLRs) that recognise pathogen-associated molecular patterns (PAMPs) (Figure 4). Mast cells have been shown to express TLR1, TLR2, TLR3, TLR4, TLR6, TLR7 and TLR9. \textit{In vitro} studies in rodents and humans have shown that TLRs can activate mast cells, and that the response is specific for each PAMP. Activation through different TLRs leads to individual patterns of cytokine production (e.g. TNF-α, IL-6, IL-13, IL-1β) with or without degranulation\textsuperscript{78,109-112}.

The anaphylatoxins, C3a and C5a of the complement system, act as potent chemotactants as well as activate mast cells and cause histamine release (Figure 4)\textsuperscript{113,114}. Furthermore, other host endogenous peptides such as neurotensin, substance P\textsuperscript{115,116} and endothelin 1\textsuperscript{117} activate mast cells and cause mediator release. Binding of the CD30 ligand to CD30 on mast cells causes degranulation-independent secretion of chemokines, such as IL-8 and macrophage inflammatory protein-1 α and β\textsuperscript{118}.

Mast Cells in Health and Disease

As described above, the role of mast cells in disease is most commonly exemplified by effector functions in allergic rhinitis and asthma (Figure 5). Several pathophysiological events important for development of allergic asthma follow upon IgE activation. Mast cells rapidly release histamine (vascular leak, hypotension, bronchoconstriction), leukotrienes and prostaglandins (vascular leak, bronchoconstriction)\textsuperscript{75}. Evidence for their role in anaphylaxis and asthma is the localisation in or near structures involved in asthma pathophysiology such as smooth muscle, glands and epithelium\textsuperscript{90}. Increased numbers of degranulated mast cells are found in post-mortem bronchial biopsies from patients who died of asthma, and increased levels of mast cell mediators are found in BAL fluid in asthmatic patients compared to healthy subjects, even without allergen provocation. Mast cells are also in part responsible for the late phase reactions observed in allergy 4–24 h after allergen provocation. This is due to the release of \textit{de novo} synthesis and release of various cytokines\textsuperscript{119}. However, murine models of allergic inflammation in the lung have shown that in mast cell or IgE deficient mice a similar degree of airway inflammation exists\textsuperscript{120}. Taking into account that mice do not naturally develop asthma, and the large differences in mast cell distribution in the airways between mice and humans might give an explanation to this phenomenon. Indeed, in other sensitization protocols, mast cells were shown to be essential for the induction of an allergic inflammation.
Figure 5. The interaction of mast cells with various structural and immunological cells, which results in different pathological processes.

Mast cells have been proven central for host survival. Mast cell deficient mice were found to be more likely to die in *Mycoplasma pulmonis* infection and in a model of acute septic peritonitis than their wild type counterparts. In other infection models, recruitment of neutrophils by rapid release of mast cell derived TNF-α is essential for host survival and clearance of pathogens. Mast cells also express receptors for direct recognition of bacteria (CD48), bacterial products (TLRs), and mediators like proteins of the complement system and endothelin-1 are upregulated during a bacterial infection. Mast cells can also directly kill bacteria by the release of cathelicidins and chymase. Some bacteria have developed protective mechanisms against mast cells, for example exotoxin A from *Pseudomonas aeruginosa* can induce mast cell apoptosis.

Exacerbations in asthma and COPD are often associated with viral infections. Several respiratory viral infections change mast cell numbers and function, where
they upon activation via for example TLR3 secrete cytokines and mediators that can activate the endothelium to recruit immune cells to the site of infection\textsuperscript{78,129-133}. Little is known about the possible contribution of the mast cell in fibrotic disorders of the lung\textsuperscript{134}. Mast cells release a vast range of cytokines, proteases and proteoglycans that can modify and direct the inflammatory response towards resolution or formation of fibrosis\textsuperscript{134}. Mast cell-derived molecules can both modify the production and destruction of extracellular matrix as well as promote migration and proliferation of fibroblasts \textit{in vivo}\textsuperscript{135-137}. Despite that mast cells have been shown to promote fibrosis in several organs\textsuperscript{138,139}, little is known regarding their role in formation of lung fibrosis. Previous studies have shown increased numbers of mast cells in bleomycin-induced pulmonary fibrosis in rats\textsuperscript{136} and in sarcoidosis\textsuperscript{135}, as well as presence of mast cells in the airways of patients with CF\textsuperscript{140,141} and increased mast cell numbers in the airways of patients with IPF\textsuperscript{142-144}. Increased chymase expression has been reported in human idiopathic interstitial pneumonia\textsuperscript{145}. Furthermore, Tchougounova \textit{et al.}\textsuperscript{146} demonstrated a possible role for chymase in mMCP-4 knockout mice, where chymase-deficient mice developed an imbalance in extracellular matrix production.

Upon parasite infection, IgE activates mast cells and in a mouse model, mast cells cause expulsion of the parasite from the intestinal mucosa by destroying the tight junction protein, occludin, by the activity of mast cell protease \textsuperscript{147}. The mast cell involvement in the adaptive immune system is currently under investigation, but has been shown in murine models to include roles as antigen presenting cells or indirectly by potentiation of lymph nodes\textsuperscript{148,149}. Mast cell activation (through IgE/FceRI or PAMPs/TLRs) promotes maturation and migration of dendritic cells to the lymph nodes, recruitment of dendritic cells from the circulation and can induce lymphnode hypertrophy. Several mast cell mediators, such as TNF-\(\alpha\) and IL-6 can activate B- and T-lymphocytes in the lymph node. Finally, various venoms from snake, honeybee, mosquito (mastoparan, MCDP and sarafotoxins) cause mast cell activation and release of proteases that can degrade and reduce the concentration of the toxic peptides\textsuperscript{78,81,133}. It is important to consider that mast cell-pathogen interactions have been predominantly studied in \textit{in vitro} settings, and that differences are found depending on cell source and culture condition. More \textit{in vivo} studies exploring the role of mast cells in non-allergic immune responses seem warranted.
Aims and Hypotheses

The general aim of this thesis was to study the distribution, heterogeneity and molecular expression pattern of human mast cells, as they appear in tissue from patients with inflammatory airway disease.

The main hypothesises of the five studies are as follows:

- The first study (paper I) tests the hypothesis that the prevailing MC\textsubscript{T} and MC\textsubscript{TC} mast cell subtypes can be further divided into site-specific populations created by the microenvironment within each anatomical compartment in the healthy human lung.

- Following studies aimed to investigate how non-allergic inflammatory responses affect the mast cell populations in the lung with regard to mast cell heterogeneity of the MC\textsubscript{T} and MC\textsubscript{TC} populations, morphology, distribution and molecular expression. This is studied in detail in different severities of COPD (paper II), and in idiopathic pulmonary fibrosis and cystic fibrosis (paper III).

- We hypothesised that the alveolar parenchyma is subjected to a mast cell-associated inflammation in patients with uncontrolled asthma (paper IV). A significant proportion of patients with asthma have persistent symptoms despite treatment and little is known regarding the inflammation and role of mast cells in the alveolar parenchyma in these patients.

- We hypothesised (paper V) that allergic rhinitis patients with concurrent asthma (but not patients with rhinitis alone) have increased mast cell expression of the high affinity IgE receptor in the alveolar parenchyma. Many patients with allergic rhinitis develop asthma over time but little is known regarding the differences in alveolar inflammation between the two diseases.
Methodology

The aim of this chapter is to give an overview of the different techniques and methodological approaches used in this thesis. Information about specific material and methods is given in detail in paper I-V. For all included papers, human lung tissue was studied with different histological techniques.

Subjects and Patient Characterisation

All subjects analysed in this thesis gave their written informed consent and the local ethics committee approved the studies. For patient details see Table 1.

Healthy Controls and Smoking Controls (Paper I-V)

In all papers, control tissues were collected from healthy non-atopic non-smoking subjects (n=16). Also smoking controls (ex- or current smokers without COPD, n = 7) were included. All control subjects had normal lung function according to criteria for each corresponding disease, negative metacholine challenge test (PD20 > 2000 μg) and negative skin prick test. Control tissues were obtained through two different methods: lung resections and bronchial- and transbronchial biopsies (see below).

Patients with COPD (Paper II)

Twenty-five subjects were included in the study and were divided into 3 COPD patient groups: patients with mild COPD (GOLD I, n = 6), moderate to severe COPD (GOLD II–III, n = 9), and very severe COPD (GOLD IV, n = 10). The patient grouping was based on GOLD classifications. Lung tissue from mild, moderate, and severe COPD was obtained in association with lung lobectomy due to suspected lung cancer, a procedure that has been used repeatedly to collect tissue from COPD patients. In patients with very severe COPD (GOLD IV), matching lung tissue was collected in association with lung transplantation.
Patients with Cystic Fibrosis (Paper III)

CF was diagnosed on the basis of clinical manifestations from the lung and gastro-intestinal tract and a positive sweat test\(^{42,152}\). In 5 patients with end-stage CF, lung tissue (20 large tissue blocks) was collected in association with lung transplantation.

Patients with Idiopathic Pulmonary Fibrosis (Paper III)

Twenty-one large lung tissue blocks from 7 IPF patients, diagnosed based on established criteria\(^5\) and confirmed by open lung biopsy was collected. Characterisation was further established after lung function tests, oxygen saturation test during exercise, blood sampling and cell profile in BAL fluid. As patients were diagnosed in relation to their inclusion in the study, they were not on treatment with any medication. The research protocol for IPF patients was approved by the Ethics Committee of the National Institute of Respiratory Diseases, Mexico City, Mexico.

Patients with Atopic Asthma and Rhinitis (Paper IV-V)

Thirty-eight non-smoking patients with confirmed allergic rhinitis (AR)\(^{153}\) were studied. Of the AR patients, 8 had a concomitant diagnosis of mild atopic asthma and 14 had a concomitant diagnosis of mild to moderate uncontrolled asthma. Diagnosis were based according to GINA guidelines and asthma control test (ACT)\(^{154}\). Among the 16 AR patients with no concomitant asthma, 8 were hyper-responsive to metacholine defined by spirometric testing (PD20 < 2000 \(\mu\)g). Central airway biopsies and transbronchial biopsies were collected at the Department of Respiratory Medicine, Lund University Hospital (see below).

Skin Prick Test

Skin prick test (SPT) (Alk Abello, Copenhagen, Denmark) was used to screen for sensitization for 10 aeroallergens (birch, timothy, mugwort, cat, dog, horse, \(D.\) pteronyssinus, \(D.\) farinae, Aspergillus fumigatus and Cladosporium herbarum). Patients with positive SPT to pollens without any other sensitivity were classified as seasonal, whereas patients with multiple sensitivities (pollen, animal, mould and/or mite) were classified as perennial. For all subjects with positive SPT to pollen, bronchoscopy procedures were performed outside pollen season.

Spirometry and Metacholine Inhalation Challenge Test

For measurements of lung function a MasterScope spirometer (v. 4.5, Erich Jaeger GmbH, Wurzburg, Germany) was used, and reference values were obtained from
Crapo. Two values of FEV\(_1\), with less than 4 % variation, were obtained and the better was recorded as baseline. If the baseline value was less than 70 % of predicted, the metacholine inhalation challenge test was aborted and patients were excluded from the study. Presence of bronchial hyper-responsiveness was measured with a metacholine inhalation challenge test, which was performed with a tidal volume triggered equipment (Aerosol Provocation System, APS; Erich Jaeger GmbH). The APS delivered a cumulative dose of 2000 µg metacholine in five increments (50, 150, 300, 600 and 900 µg) following an initial dose of 0.9% NaCl. If the FEV\(_1\) declined more than 20% during the test the challenge was aborted. A positive test was defined as the cumulative dose that caused a decline in FEV\(_1\) by 20% or more from baseline. When FEV\(_1\) fell below 80% of the baseline value or when the total amount of 2000 µg metacholine was delivered, 400 µg of salbutamol was given to the subject. After 10 min a new flow-volume spirometry was carried out, to ensure that the subjects were recovering accurately.

**NO measurement**

Measurements were performed as previously described. Briefly, FeNO measurements were done prior to bronchial challenge test at a flow rate of 50, 100, 200 and 400 ml/s using a NIOX nitric oxide analyser (Aerocrine AB, Stockholm, Sweden) and the results were expressed as parts per billion (ppb). Alveolar NO concentration and bronchial flux of NO were calculated with a two-compartment linear model using a flow rate of 100–400 ml/s.

**Impulse Oscillometry**

A Jaeger MasterScreen Impulse Oscillometry System, Erich Jaeger GmbH, was used 90 s after each step of the challenge, prior to FEV\(_1\) (as previously described). Resistance was reported as R5 (total respiratory resistance of the airways) and R20 (resistance of the proximal airways). The ΔR5-R20 parameter is an indicator of peripheral resistance of the respiratory tract. Resonant frequency (Fres) is a good index of changes of the degree of peripheral involvement. The IOS parameters were plotted against the metacholine dose at each challenge step and linear regression analysis was used to calculate a slope value.

**Tissue Acquisition and Processing**

When possible, care was taken to immerse the tissues from patients and controls in fixative immediately after surgical excision and multiple large tissue blocks were prepared for histological analysis.
**Lung resections**

Tissue was obtained from lung lobectomy samples resected from patients undergoing surgery due to suspected lung cancer. Only patients with solid, well-delineated tumours were included, and tissue samples were obtained as far as possible from the tumour. This procedure has commonly been used to collect human tissue from never-smoking and smoking controls as well as from COPD patients\(^{70,71}\).

**Bronchial and Transbronchial Biopsies**

Bronchoscopy was performed after local anaesthesia with a flexible bronchoscope (Olympus IT160, Tokyo, Japan) and transbronchial biopsies were taken with biopsy forceps (Olympus FB211D) under fluoroscopic guidance in the peripheral right lower lobe, not closer than 2 cm from the chest wall. Before bronchoscopy, the subjects received oral Midazolam (1mg per 10kg) and i.v. Glykopyrron (0.4 mg). Local anaesthesia was given as Xylocain spray; local and through spray catheter. Just before the procedure, alphentanyl 0.1-0.2mg / 10kg bodyweight was given intravenously and extra Midazolam i.v. was given as needed. Central airway biopsies (n=5) were taken from the segmental or sub segmental carina in right lower and upper lobe, followed by transbronchial (n=5) in right lower lobe. Oxygen was given as needed under and after the procedure. Fluoroscopy of the right lung was done immediately after and 2 hours after the procedure in order to rule out significant bleeding or pneumothorax. 3-4 mg betamethasone was given to prevent eventual fever reactions and the subject was discharged after 2 hours observation.

**Formalin Fixated and Paraffin-Embedded Tissue**

Samples (paper I-IV) were placed in 4% buffered formaldehyde, dehydrated, and embedded in paraffin. From each block, a large number of sequential sections 3 µm in thickness were generated.

**Periodate Lysine Paraformaldehyde Fixated Tissue**

Samples (paper IV and V) were fixed in periodate-lysine containing 1% paraformaldehyde (1% PLP) for 4 h at 4°C. Specimens were embedded in OCT (Tissue-Tek, Miles Laboratories, IN), and stored at -80°C. Cryosections were cut serially at 8 µm and enwrapped in aluminium foil, and stored at -80°C until used.
Tissue Processing for Electron Microscopy

After tissue fixation (paper I-II) in buffer supplemented with 1% glutaraldehyde and 3% formaldehyde overnight, samples were rinsed in buffer, post-fixed in 1% osmium tetroxide for 1 h, and dehydrated in graded acetone solutions and embedded in Polarbed 812. One-µm thick toluidine blue stained plastic sections were examined by bright field microscopy and areas with a well-preserved morphology were selected for electron microscopic analysis. Ultrathin sections (90 nm) were cut and placed on 200-mesh, thin bar copper grids before staining with uranyl acetate and lead citrate.¹⁵⁸

Histology and Immunohistochemistry

Mayer’s Haematoxylin and Masson’s Trichrome-Staining

Mayer’s haematoxylin (HTX) staining was used both as counterstain in immunohistochemistry procedures and as complete HTX and eosin staining used for morphological evaluation. HTX-Eosin stains cell nuclei blue and cell cytoplasm red. Masson’s trichrome-staining visualise collagen fibres bright blue, muscle, cytoplasm and keratin red and cell nuclei black and was used for morphological evaluation in tissue from patients with fibrotic lesions. The trichrome staining was also used to measure the degree of fibrosis in the lungs of patients with CF and IPF in paper III. A scoring system¹⁵⁹ as well as measuring of the density of collagen (based on the blue staining using a image analysis program) were applied to the sections.

Double Immunohistochemical Staining of MCₜ and MCₜc

A modified double-staining technique was developed to stain for mast cell subtypes, mucosal mast cells (MCₜ, positive for tryptase) and connective tissue mast cells (MCₜc, positive for chymase and tryptase), in the same section. Paraffin sections were pre-treated with a high-temperature antigen unmasking technique (pressure cooking, DIVA buffer, pH 6, for 20 min; Biocare Medical, Concord, CA or PT Link, target retrieval solution low pH, Dako, Glostrup, Denmark). The immunohistochemical staining was performed with an automated immunohistochemistry robot (Autostainer; DakoCytomation) with EnVision™ G|2 Doublestain System (K5361; Dako). Sections were blocked with dual endogenous enzyme block for 10 minutes, then incubated with primary antibody (mouse monoclonal anti-mast cell chymase) for 1 hour, incubated with an HRP-conjugated polymer for 30 min and developed using the HRP substrate DAB as chromogen. By saturating all chymase-positive mast cells with a dark brown DAB (3,3’-diaminobenzidine) precipitation staining, they become inert to further mast cell tryptase staining due to that the precipitated DAB complex constitutes a steric hindrance for any further antibody binding. Next, sections were blocked using double
stain block reagent (making the first antibody inert to further staining by chemically destroying the antigenicity) and were incubated with mouse monoclonal anti-mast cell tryptase for 1 hour at room temperature. This was followed by Rabbit/Mouse link and incubation with an AP-polymer and visualisation with Permanent Red or New Fuchsin chromogen. Background was visualised with HTX staining and sections were mounted in Pertex mounting medium (Histolab, Gothenburg, Sweden). The resulting staining showed MC_{TC} cells as dark brown and the MC_{T} population appeared bright red.

**Immunohistochemical Triple-Staining**

Slides were pre-treated using a high-temperature antigen unmasking technique with appropriate target retrieval solution. Paraffin sections were blocked for unspecific binding in normal serum from the species in which the secondary antibody was produced, mixed with or without dry milk (Vector Laboratories, Burlingame, CA) at ambient temperature. Sections were blocked for endogenous streptavidin and biotin with avidin/biotin blocking kit (Vector Laboratories, Burlingame, CA) and incubated with primary antibodies against the molecules of interest. After a rinsing step, sections were incubated for 1 hour at ambient temperature with the biotinylated secondary antibody and fluorescence conjugated streptavidin (1:200, 10 µg/ml, S21381; Molecular Probes, Eugene, OR) for 30 minutes at ambient temperature. To stain the same sections for mast cell subtypes (MC_{T} and MC_{TC}), the mouse monoclonal antibodies used in the double staining described above, anti-mast cell tryptase and anti-mast cell chymase, were directly labelled with Alexa Fluor 488 and Alexa Fluor 350, respectively, using Zenon® Mouse IgG labelling kit (Invitrogen, Molecular Probes). Sections were incubated with the mixed solutions for 1 hour at ambient temperature and mounted in TBS/glycerol mounting medium. All rinse steps were in TBS buffer (pH 7.6).

**Detection of Apoptotic Mast Cells in Lung Tissues with the TUNEL Technique**

Paraffin-embedded sections (3 µm) were deparaffinised and pre-treated with proteinase K (20 µg/ml; Sigma, Stockholm, Sweden) for 15 min at room temperature. Apoptotic cells were visualised using the TUNEL technique according to the manufacturer’s instructions (ApopTag Fluorescein In Situ Apoptosis Detection Kit, S7110; Chemicon/Millipore, Billerica, MA). Apoptotic cells were visualised with a sheep anti-digoxigenin fluorescein (FITC) antibody. No staining was evident in negative controls when the terminal deoxynucleotidyl transferase (TdT) enzyme was omitted. Mast cells were detected using primary antibody to tryptase (1 h at ambient temperature) and visualised with an Alexa-555 conjugated secondary goat anti-mouse antibody (Invitrogen, Molecular probes, Eugene, OR). Slides were counterstained with the DNA-binding
stain Hoechst 33342 (Sigma) to show the total number of cell nuclei. As positive control, dexamethasone-treated thymus was used.

**Antibody Specificity Controls**

The antibodies used in this thesis have been used extensively in research and routine pathological examinations of human formalin-fixed, paraffin-embedded material and most antibodies have also been validated and certified for pathology-based diagnosis. All antibodies showed relevant biological staining in accordance with previous literature. Staining was absent in sections omitting the primary antibody. For all immunohistochemical procedures, markers and tissues, staining were also absent in sections using isotype-matched control antibodies (Dako) that were used instead of, and in the same concentration as, the primary antibody. The mouse monoclonal isotype IgG1 and IgG2 controls are antibodies against Aspergillus niger glucose oxidase, an enzyme which is neither present nor inducible in mammalian tissues. The rabbit negative control immunoglobulin fraction was isolated from serum of healthy non-immunised rabbits.

**Measurements**

**Quantification of Mast Cell Densities in Lung Compartments**

From each section double stained for $\text{MC}_T$ and $\text{MC}_{\text{TC}}$, the density of each population was quantified manually in blinded images and related to the tissue area. Ultra-high resolution digital images (> 4 GB) were generated by an automated slide scanner robot equipped with an x20 microscope lens (Image Scope, v10.0.36.1805, and ScanScope FL, Aperio, Vista, CA). After manual delineation of each analysed compartment (i.e. large airway walls, small airway walls, pulmonary vessel walls and alveolar tissue), the analysed tissue area was calculated through computerised image analysis using virtual microscopy software. The image analysis program automatically excluded any air spaces, so that only true tissue was measured. For lung resections and transplantation tissue, each tissue section comprised > 4 cm$^2$ lung tissue and contained several small airways, pulmonary vessels as well as differentially altered alveolar parenchyma, allowing for comparisons between the following key compartments: Large airways: bronchi, defined by a diameter > 2 mm and regular or intermittent occurrence of cartilage. Small airways: bronchioles, defined by absence of cartilage and diameter < 2 mm. When appropriate, mast cells were evaluated in large and small airway epithelium, lamina propria, smooth muscle and adventitia. Pulmonary vessels: mid-size pulmonary arteries in the broncho/bronchiovascular axis or with an intra-acinar localisation. Mast cells were counted in intima, media and adventitia. Alveolar parenchyma: Four randomly selected 0.5 mm$^2$ alveolar regions were analysed in each lung section. Due to the heterogeneity of diseased alveolar parenchyma (paper III), each slide was assessed for mast cells in the
following category of parenchyma: normal, or nearly normal parenchyma (defined as absent or minimal fibrous thickening of alveolar walls and only few scattered inflammatory cells); inflammatory parenchyma (areas with significant leukocyte infiltration, often accompanied by some alteration of alveolar structure); and fibrotic parenchyma (fibrotic lesions and regions with excessive collagen deposition, as revealed by Masson’s trichrome staining in consecutive sections). For bronchial and transbronchial biopsies (paper I, IV and V), all mast cells of each subpopulation per biopsy were quantified manually in randomised, blinded images of central airways and alveolar parenchyma. In bronchial biopsies the densities of MC\(_T\) and MC\(_{TC}\) were also calculated in sub-anatomical compartments: epithelium, subepithelial tissue (excluding smooth muscle and glands), smooth muscle tissue and subepithelial glands. The proportion of the MC\(_{TC}\) subtype in each compartment was calculated according to \((\text{MC}_{TC} / [\text{MC}_{TC} + \text{MC}_T]) \times 100\).

**Expression of Mast Cell-Related Molecules**

The markers in paper I-V were selected to reflect activation status and possible roles for mast cells in normal conditions, chronic inflammation and in the formation of fibrosis. Sections were analysed using NIS-elements AR 3.0 system (Nikon, Tokyo, Japan), a Nikon Eclipse 80i microscope, and a Nikon DS-Qi1Mc camera. After triple immunofluorescence staining, filter setting was adjusted to reveal the tryptase-positive mast cells at 488 nm. By alternating the filter settings each tryptase-positive cell was examined for presence of chymase as well as expression of mast cell-related molecules. By dividing the number of tryptase\(^+\)/chymase\(^-\) and tryptase\(^+\)/chymase\(^+\) cells that were co-positive for the molecule of interest, the proportion of co positive mast cells of total number of mast cells, MC\(_{TC}\) and MC\(_T\) was calculated. In papers IV and V also the density of mast cells expressing Fc\(\epsilon\)RI and IgE was calculated by multiply the percentage of MC\(_{'F\epsilonRI^+}\) or MC\(_{'IgE^+}\) with the total mast cell density in the same tissue region.

**Size and Shape Analysis**

In paper I and II, the average cross section size was calculated for both MC\(_T\) and MC\(_{TC}\) in each major compartment of the lung. Cell size was measured with manual cursor tracing at high resolution digital images using software Image J (version 1.34s, National Institutes of Health, USA). MC\(_T\) and MC\(_{TC}\) were visualised in the same section by double staining (see above). The size measurements used in the main study were performed on foremost cross-sectioned airways and pulmonary vessels. To exclude any misleading results from an uneven or biased sectional plane we analysed cell sizes in a large numbers of longitudinally sectioned airways and vessels. To further improve our quantification of mast cell sizes we employed a stereological approach using volume fraction measurements from a fixed cell number quantification \(^{161}\). In short, using a point grid overlaid onto randomly orientated tissue sections point counting was performed until a fixed numbers of mast cells (240 /patient) were hit by one or more points. With similar cell
numbers analysed differences in volume fraction will equate differences in mean cell size. The volume fraction for each mast cell subtype and compartment was calculated using the equation:

\[ V_{v (MC, \text{compartment})} = \frac{\sum P(MCT, MCTC)}{\sum P(SA, PV)} \]

Where P is points counted, SA denotes the small airways compartment and PV is pulmonary vessels. The cell shape was calculated using the formula: circularity = \(4\pi \frac{\text{area}}{\text{perimeter}^2}\).

**Transmission Electron Microscopy**

In each lung compartment samples were processed and analysed by routine transmission electron microscopy using a standard protocol\(^{162}\). Mast cell subtypes and the degranulation status of each individual mast cell were analysed according to established ultra structural characteristics\(^{88}\) and the results were scored according to the following categories: no degranulation (completely filled granules with characteristic scroll or crystalline pattern), mild piecemeal degranulation (presence of granules with loss of structural organization and electron density and absence of granule fusions to the plasma membrane\(^{88}\)), advanced piecemeal degranulation (the majority of granules partially or completely empty and abundant secretory vesicles) and classical anaphylactic degranulation (granule swelling, fusion, or degranulation channel formation and occurrence of extracellular granules\(^{163}\)).

**Statistical Analyses**

Data were analysed statistically using Kruskal-Wallis test with Bonferroni’s multiple comparisons test for comparison between three groups or more and Mann-Whitney rank sum test for comparison between two groups, using GraphPad Prism v. 5 (GraphPad Software, Inc., La Jolla, CA). For correlation between lung function values and mast cell parameters, Spearman rank correlation test (two-tailed) was used. To compensate for multiple testing, the false discovery rate procedure was applied to the correlation analysis, which guarantees that less than 5% of all positive results are false positive\(^{164}\). Results were considered significant at \(p \leq 0.05\).
<table>
<thead>
<tr>
<th></th>
<th>Healthy controls</th>
<th>Healthy smokers COPD (GOLD I-IV)</th>
<th>CF</th>
<th>IPF</th>
<th>Uncontrolled asthma</th>
<th>Mild asthma</th>
<th>Allergic rhinitis (without/with BHR)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of patients (n)</strong></td>
<td>16 (8+8)</td>
<td>7</td>
<td>25</td>
<td>5</td>
<td>14</td>
<td>8</td>
<td>16 (8+8)</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>63 (33-76)</td>
<td>56 (47-68)</td>
<td>64 (52-76)</td>
<td>30 (23-38)</td>
<td>64 (57-70)</td>
<td>40 (22-59)</td>
<td>28 (22-37)</td>
</tr>
<tr>
<td></td>
<td>23 (21–39)</td>
<td>16 (21–39)</td>
<td>56 (47-68)</td>
<td>30 (23-38)</td>
<td>64 (57-70)</td>
<td>40 (22-59)</td>
<td>28 (22-37)</td>
</tr>
<tr>
<td><strong>Male/Female</strong></td>
<td>2/6</td>
<td>3/4</td>
<td>16/9</td>
<td>2/3</td>
<td>0/7</td>
<td>9/5</td>
<td>5/3</td>
</tr>
<tr>
<td><strong>Tissue acquisition</strong> (n=number of tissue blocks)</td>
<td>Lung resections (n=28)</td>
<td>Lung resections (n=21)</td>
<td>Lung resections (n=75)</td>
<td>Lung transplantation (n=20)</td>
<td>Open lung biopsy (n=21)</td>
<td>EBBX (n=40/16) TBBX (n=20)</td>
<td>EBBX (n=40/16) TBBX (n=40/16)</td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhaled GCS (yes)</td>
<td>No</td>
<td>No</td>
<td>10</td>
<td>5</td>
<td>No</td>
<td>14</td>
<td>No</td>
</tr>
<tr>
<td>Oral GCS (yes)</td>
<td>No</td>
<td>No</td>
<td>1</td>
<td>3</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>β2 agonist (yes)</td>
<td>No</td>
<td>No</td>
<td>12</td>
<td>5</td>
<td>No</td>
<td>14</td>
<td>5</td>
</tr>
<tr>
<td>Anticholinergics (yes)</td>
<td>No</td>
<td>No</td>
<td>9</td>
<td>1</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Mucolytic (yes)</td>
<td>No</td>
<td>No</td>
<td>8</td>
<td>5</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Lung function</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 % pred.</td>
<td>110 (82–141)</td>
<td>97.4 (82–120)</td>
<td>56.5 (13-95)</td>
<td>31 (22-45)</td>
<td>82 (66-93)</td>
<td>81.2 (63-108)</td>
<td>96.4 (88-124)</td>
</tr>
<tr>
<td>FEV1 / FVC</td>
<td>86 (66–121)</td>
<td>78.1 (71–88)</td>
<td>49.7 (17-70)</td>
<td>50 (33-84)</td>
<td>90 (82-99)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MC+/MC−</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Expression pattern</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes (FcεRI/IgE)</td>
<td>Yes (FcεRI/IgE)</td>
</tr>
<tr>
<td>Microlocalisation</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes (FcεRI/IgE)</td>
<td>Yes (FcεRI/IgE)</td>
</tr>
<tr>
<td>Apoptosis</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes (FcεRI/IgE)</td>
<td>Yes (FcεRI/IgE)</td>
</tr>
<tr>
<td>Morphology (size/shape)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>TEM (degranulation)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Correlation study</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

BHR = bronchial hyperreactivity. GCS = glucocorticosteroids. * number of specimens selected for the mast cell analyses, ** healthy control (tissue acquisition: lung resection), *** healthy control (tissue acquisition: bronchoscopy), **** allergic rhinitis without BHR, ***** allergic rhinitis with BHR.
Results

**Novel Site-Specific Mast Cell Subpopulations in the Human Lung (Paper I)**

*In vivo* data on human lung mast cells, particularly in peripheral regions, have remained scarce. There are indications that division into MC\textsubscript{T} and MC\textsubscript{TC} does not adequately explain the complexity of lung mast cell heterogeneity. Based on these notions we hypothesised that among the anatomical compartments of the lung there is a site-specific heterogeneity that is present already under non-inflamed healthy conditions and goes beyond the MC\textsubscript{T} and MC\textsubscript{TC} classification. The present study explores this possibility through detailed assessments of morphometric and molecular characteristics of lung tissue mast cell populations under base-line conditions. These parameters were investigated in multiple lung structures by immunohistochemistry and electron microscopy. Fifteen non-smoking subjects with normal lung function were investigated.

**MC\textsubscript{T} and MC\textsubscript{TC} are abundant at all airway levels with a gradual increase towards peripheral regions**

Mast cells were abundant at all airway levels with a gradual and statistically increased density towards the alveolar parenchyma. In all major anatomical compartments, except in the adventitia of pulmonary vessels and the pleural wall, MC\textsubscript{T} was the predominant subtype (Figure 6A).

**MC\textsubscript{T} and MC\textsubscript{TC} may be divided into site-specific subgroups**

By measuring cell cross-section areas it was revealed that the size within each of the MC\textsubscript{T} and MC\textsubscript{TC} populations differed dramatically between anatomical regions. Large MC\textsubscript{T} cells were found in bronchi, small airways and alveolar parenchyma and significantly smaller MC\textsubscript{T} were present in pulmonary vessels. For MC\textsubscript{TC} a reversed pattern was found, i.e. large MC\textsubscript{TC} in pulmonary vessel walls, and a significantly smaller MC\textsubscript{TC} population in bronchial and small airway walls and alveolar parenchyma. Distinct size changes were further corroborated by stereology where distinct volume fractions were present after analysis of equal mast cell numbers. Calculation of the circularity showed that MC\textsubscript{TC} cells were significantly more circular in all compartments compared to neighbouring MC\textsubscript{T} cells in the bronchial wall, small airways, and pulmonary vessels. Ultrastructural examinations of MC\textsubscript{TC} and MC\textsubscript{T} subtypes, identified by their distinct
granule morphology, revealed that in all examined compartments mast cells were of a non-degranulated phenotype.

Distinct expression of mast cell-related molecules in site-specific \(MC_T\) and \(MC_{TC}\) populations

When different lung compartments were examined, a significant difference in mast cell FcεRI expression was found, from an extensive expression in bronchi, moderate in small airways, and a virtually absent expression on alveolar mast cells. A similar pattern was seen in bronchial and transbronchial biopsies from the young control population. The expression of HDC followed the same pattern as the FcεRI. Renin, just recently discovered as an airway mast cell mediator, showed significantly elevated expression in the pulmonary vessels and the distal airways compared to the other compartments of the lung. Differences in mast cell expression of 5-LO, LTC\(_4\)-S, IL-9R, FGF-2 and VEGF were found, not only between the \(MC_T\) and \(MC_{TC}\) subpopulation, but also between each compartment (Figure 6B).

Figure 6. Mast cell densities (A) and a summary of the molecular expression pattern in \(MC_T\) (B) in different compartment of the healthy human lung.

Marked Alterations of Lung Mast Cell Populations in Patients with COPD (Paper II)

Mast cells have been asserted roles in innate immunity, immune orchestration, and tissue remodelling. Since mast cells are present in high numbers throughout the human lung, this suggests potential involvement in non-allergic inflammatory diseases like COPD.
**Alteration of mast cell numbers in COPD**

In both control and COPD subjects, mast cells were present at all anatomical compartments of the lung. A decrease in total mast cell numbers was found in small airways in patients with COPD (GOLD IV) compared to non-smoking and smoking controls. The total density of mast cells in pulmonary vessel walls also decreased significantly in very severe COPD when compared to non-smokers, smokers and GOLD I-III. No difference in total numbers were found in the alveolar septa of the parenchyma as the different groups were compared.

**COPD lungs have increased proportion of $MC_{TC}$**

Division into $MC_T$ and $MC_{TC}$ populations revealed that in all compartments of the lung there was a gradual and significant decrease in $MC_T$ density as the severity of COPD increases (Figure 7B-D). In contrast, in small airway walls and alveolar parenchyma the density of $MC_{TC}$ increased significantly in COPD (GOLD IV). In pulmonary vessels the density of both subpopulations dropped significantly in COPD (GOLD IV). In very severe COPD scattered submucosal glands were present in association with airways in the peripheral lung. Notably in these structures, $MC_{TC}$ comprised 95% of the total mast cell density. Bronchial mast cell densities in large airway tissue were analysed in separate biopsies and lung resections of non-smoking controls and COPD (GOLD IV). In central airways in COPD (GOLD IV) a decreased total number of mast cells, and an increased $MC_{TC}$ proportion, were shown compared to controls.

**$MC_T$ and $MC_{TC}$ cells have altered distributions in small airways and pulmonary vessels**

The distribution of mast cells was analysed in more detail in sub-anatomical compartments within the small airways and pulmonary vessels. In summary, in small airways from COPD patients there was a shift in relative mast cell densities from the outer to the inner wall layers (epithelium and lamina propria). For both $MC_T$ and $MC_{TC}$ the percentage of intraepithelial mast cells increased significantly in very severe COPD while the proportion of both subtypes decreased in the smooth muscle and adventitia layers.

**Mechanisms for clearance of lung mast cells**

In light of the decreased numbers of total mast cells in COPD possible mechanisms for mast cell elimination were investigated. Screening of >5000 mast cells / patient and large numbers of TUNEL-positive nuclei (mostly neutrophils) revealed that co-localization in mast cells was exceedingly rare. In patients with COPD (GOLD IV), luminal $MC_T$ cells mast cells were readily observed and significantly increased in numbers compared to control groups and COPD groups with milder disease, which might indicate elimination of mast cells through luminal entry or epithelial shedding.
Altered \( MC_T \) and \( MC_{TC} \) phenotypes in COPD

Ultrastructural examination of lung mast cells by transmission electron microscopy was performed on very severe COPD lungs and non-smoking controls. Mast cells in non-smoking subjects were of a non-degranulating phenotype i.e. displayed filled granules lacking morphological signs of anaphylactic or piecemeal degranulation. Although most of the mast cells in COPD were of a non-degranulating phenotype, cells displaying signs of mild to moderate piecemeal degranulation were readily found. In small airways the cross-section \( MC_{TC} \) area in controls was significantly lower than in patients with very severe COPD. The expression of the mast cell related molecules CD88, TGF-\( \beta \) and renin were changed in patients with COPD compared to controls. The percentage of mast cells expressing the C5a receptor (CD88) and TGF-\( \beta \) increased significantly in all COPD groups compared to non-smoking and smoking controls. In patients with COPD the most pronounced increase was observed for the \( MC_{TC} \) subclass. The expression of mast cell renin was high at baseline conditions. COPD lungs, particularly those affected by more severe disease (GOLD II-IV), were associated with a significant decrease in renin expression.

![Figure 7](image)

**Figure 7.** Representative micrographs of immunohistochemical double staining of \( MC_T \) (red) and \( MC_{TC} \) (brown) in small airways from a healthy subject (A) and a patient with COPD GOLD IV (B). Scale bars: A = 100\( \mu \)m, B = 200\( \mu \)m. The density of \( MC_{TC} \) in small airways (C) and alveolar parenchyma (D) in smoking and never-smoking controls and COPD GOLD I-IV.
Correlations

For the COPD patient groups several highly statistical correlations were found between mast cell and lung-function parameters (FEV\textsubscript{1}/VC and FEV\textsubscript{1} % predicted). In all anatomical compartments there was a positive correlation between decreased densities of total or MC\textsubscript{T} mast cells and reduced lung function. For MC\textsubscript{TC} increased densities within small airways and the lung parenchyma correlated with reduced lung function.

Activated Connective Tissue Mast Cells Infiltrate Diseased Lung Areas in Cystic Fibrosis and Idiopathic Pulmonary Fibrosis (Paper III)

Although mast cells are regarded as important regulators of inflammation and tissue remodelling, their role in cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF) has remained poorly studied. The present study compares the densities and phenotypes of mast cell populations in multiple compartments in lungs from patients with CF, IPF and never smoking controls. Sections stained with Masson’s trichrome revealed extensive alterations of lung structures in all CF and IPF patients.

Change in densities of MC\textsubscript{T} and MC\textsubscript{TC} populations in key anatomical compartments in CF and IPF compared to controls

In patients with CF, a significant decrease in total mast cell density was observed in small airways and pulmonary vessels. The total number of mast cells were increased in fibrotic and inflamed areas of the alveolar parenchyma in CF patients. In the inflamed parenchyma this was due to increased numbers of MC\textsubscript{T} and MC\textsubscript{TC} whereas only the density of the MC\textsubscript{TC} population increased in fibrotic parenchyma. The preserved total mast cell numbers observed in small airways of IPF patients were a result of a decrease in MC\textsubscript{T} and a parallel increase in MC\textsubscript{TC} numbers. A significant decrease in total mast cell numbers was observed in pulmonary vessels in IPF. Furthermore, an increase in the density of the MC\textsubscript{TC} population was found in the inflammatory parenchyma of IPF patients (Figure 8).

Calculation of the MC\textsubscript{TC} percentage of the total mast cell population revealed that there was a shift towards a MC\textsubscript{TC} phenotype in lungs from patients with CF and IPF. In CF, the increase in the proportion of MC\textsubscript{TC} cells was found in small airways, and in normal as well as fibrotic areas of parenchyma. In IPF affected lungs, an increase in the proportion of MC\textsubscript{TC} was found in small airways, pulmonary vessels as well as in normal, inflammatory and fibrotic areas of the parenchyma (Figure 8).
Figure 8. Micrographs of alveolar parenchyma with interstitial fibrosis from a patient with IPF stained for MC_T (red) and MC_TC (brown) (A). Scale bar = 300 µm. The proportion of MC_TC in alveolar parenchyma from patients with CF, IPF and healthy controls.

Increased mast cell expression of IL-6 and TGF-β in CF and IPF
In lungs from CF patients, the total mast cell expression of IL-6 was increased in small airways, pulmonary vessels and alveolar parenchyma compared to controls. No difference in mast cell expression of IL-6 was observed in the IPF lungs compared to control subjects. A significantly increased MC_TC expression of TGF-β was observed in all compartments analysed in both CF and IPF.

Correlation of mast cell parameters with lung function and degree of fibrosis
The percentage of MC_TC in small airways and the density of MC_TC per mm² in fibrotic alveolar parenchyma correlated negatively with lung function values in the CF and IPF patients. Both the density as well as the percentage of MC_TC correlated positively with the degree of fibrosis and the density of collagen.

Mast cell-Associated Alveolar Inflammation in Patients with Atopic Uncontrolled Asthma (Paper IV)
A significant proportion of patients with asthma have persistent symptoms despite treatment with ICS. We hypothesised that in these patients the alveolar parenchyma is subjected to a mast cell-associated inflammation.

Characterisation of mast cell phenotypes in uncontrolled asthma and healthy controls
In central airways, the total tissue density of mast cells did not differ between patients with uncontrolled asthma and healthy control subjects. In contrast, the alveolar parenchyma displayed increased numbers of mast cells in patients with uncontrolled asthma compared to healthy controls. The unaltered total mast cell numbers in central airways
in uncontrolled asthma were a result of decreased $MC_T$ and increased $MC_{TC}$ numbers compared to healthy controls. The significant increase in total alveolar mast cell numbers in uncontrolled asthmatics was due to an increase in both $MC_T$ and $MC_{TC}$ numbers compared to healthy controls. The densities of $MC_T$ and $MC_{TC}$ were also calculated in sub-anatomical regions within bronchial biopsies. The highest density of mast cells was found in the lamina propria for both control subjects and asthmatics. The $MC_{TC}$ density increased in the smooth muscle layer in asthmatics compared to controls. No difference in the distribution of the $MC_T$ subclass was found in asthmatics compared to controls.

**Expression of FcεRI and IgE on bronchial and alveolar mast cells**

The proportion of mast cells expressing FcεRIα was high in central airways in healthy subjects, and no significant difference was found in uncontrolled asthmatics. In the alveolar parenchyma, the mast cell expression of FcεRIα was low in healthy controls and significantly higher in uncontrolled asthma. To further confirm the increased FcεRIα expression in uncontrolled asthma, a computerized image analysis approach was used to calculate the area of FcεRIα immunoreactivity on individual mast cells. This analysis showed an increase in FcεRIα expression in central airways of asthmatics compared to controls. A similar increase was found in the alveolar parenchyma in asthmatics compared to controls. In the alveolar parenchyma, the proportion of IgE+ mast cells was low in controls and significantly increased in the alveolar parenchyma of asthmatics. Similar results were found in the bronchi. In alveolar parenchyma, the tissue density of FcεRIα and IgE positive mast cells was increased in uncontrolled asthmatics compared to controls (Figure 9).

![Figure 9](image.png)

Figure 9. Density of mast cells expressing FcεRIα (A) and mast cell bound IgE (B) in alveolar parenchyma in uncontrolled asthma compared to healthy controls. Insets represents images (600×) of mast cells double positive for tryptase (green) and FcεRIα or IgE (red).
FeεRI and IgE expression on alveolar mast cells in AR and non-allergic inflammatory diseases

No significant change in total mast cell numbers or density of MC$_T$ and MC$_{TC}$ was found in central airways or alveolar parenchyma in patients with AR compared to healthy controls. Furthermore, no increase in the proportion of mast cells expressing FeεRIα or IgE could be found in central airways or alveolar parenchyma. However, an increase in the proportion of mast cells expressing surface bound IgE was found in alveolar parenchyma in patients with AR compared to controls.

The FeεRIα expression was high in central airways in controls compared to the same compartment in COPD and CF. In alveolar parenchyma, the mast cell FeεRIα expression was low in controls; no significant change was found in COPD and CF patients.

Alveolar Mast Cell Expression of FeεRI Differs between Allergic Asthma and Rhinitis (Paper V)

A significant proportion of patients with AR develop asthma over time. We hypothesised that AR patients with concurrent asthma (but not patients with AR alone) have increased mast cell expression of the high affinity IgE receptor (FeεRI) in the alveolar parenchyma.

Mast cell densities in central airways and alveolar parenchyma

No significant difference in total mast cell numbers or in the density of the two subtypes, MC$_T$ and MC$_{TC}$, was found between the healthy controls, AR with and without BHR and AR with concomitant asthma.

Mast cell expression of FeεRI and mast cell-bound IgE in central airways and alveolar parenchyma

In healthy controls mast cells positive for FeεRIα were present in high numbers in central airways. No significant change was observed in patients with AR with or without BHR or in AR patients with concurrent asthma compared to non-atopic controls. In alveolar parenchyma, the mast cell expression of FeεRIα was low in non-atopic controls and in AR with or without BHR. A significant increase in both proportion and density of FeεRIα expressing mast cells was found in AR patients with concomitant asthma compared to healthy non-atopic controls and patients with AR alone (Figure 10).

In central airways, the proportion of mast cells positive for surface bound IgE was low in healthy controls. A significant increase in mast cells with positive staining for IgE was observed in AR with concurrent asthma. In the alveolar parenchyma, the proportion of mast cells with IgE was low in controls and AR without and with BHR. A significant increase in the proportion and the density of mast cells with IgE was observed
in the alveoli in patients with AR with concurrent asthma compared to non-atopic controls.

**Figure 10.** Density of mast cells expressing FcεRIα (A) and mast cell bound IgE (B) in alveolar parenchyma in healthy non-atopic controls, AR patients and asthma patients with and without BHR.

**Correlation analyses**

Significant negative correlations were found between PD_{20} and bronchial mast cell expression of FcεRIα and IgE. The bronchial NO flux and FeNO50 correlated positively with mast cell bound IgE in the bronchi. The alveolar mast cell expression of FcεRIα correlated positively with Slope-Fres^{MCh}. No correlations between mast cell parameters and R5, R20 and R5-R20 were found.
Discussion

The phenomenon of mast cell heterogeneity has been known for decades and studied in several species. Apart from the prevailing classification into MC_T and MC_TC, this phenomenon has remained poorly investigated, especially under human in vivo conditions. Paper I in this thesis describes an expansion of the heterogeneity concept by showing that already under base-line conditions each anatomical compartment of the lung contains distinct MC_T and MC_TC populations with regard to morphology and mediator expression. How this heterogeneity changes under diseased conditions were studied in paper II-V.

Altered balance of MC_T and MC_TC in diseased lung

As previously described, mast cells in our studies were abundant in all lung regions and the MC_T subtype was by far the most common in the healthy human lung (paper I). MC_TC are the predominating subtype in several non-respiratory compartments like the dermis of the skin whereas there is a strong domination of MC_T in mucosa-lined organs like the respiratory tract. In COPD affected lungs (paper II), the MC_T population decreased markedly and there was an actual expansion of the MC_TC population. MC_TC cells increased in absolute numbers in both small airways and the alveolar parenchyma resulting in a shift in the MC_TC/MC_T balance. Balzar et al., showed that in lungs with severe asthma there was a similar increase in MC_TC but these changes, unlike our results, correlated to improved lung function values. A study by Gosman et al., did not report any increase in MC_TC density but this may be explained by the fact that the COPD group in this study consisted of mixed disease severities and the present data suggest that the shift may only be evident in advanced disease. A marked expansion of the MC_TC population was also found in the small airways in IPF and remodelled parenchyma in CF and IPF (paper III). The expansion of the MC_TC population in CF and IPF may have several consequences in lung remodelling processes. Hirata et al., showed that increased chymase expression in human idiopathic interstitial pneumonia, correlated with increased numbers of IL-4 expressing cells, smooth muscle cells and myofibroblasts. Furthermore, Tchougounova et al., demonstrated a possible role for chymase in mMCP-4 knockout mice, where chymase-deficient mice developed an imbalance in extracellular matrix production. The previous research on mast cells in association with remodelling and fibrosis is limited, but increased numbers of mast cells have been found in animal models of fibrosis and mast cells have been shown to affect biochemical properties of lung fibroblast function in vitro. Pesci et al.
found increased numbers of mast cells in patients with fibrotic lung disorders, which correlated significantly with the degree of fibrosis. We found increased density of $MC_{TC}$ in the lungs of patients with atopic uncontrolled asthma (paper IV). This phenomenon was not seen in patients with mild asthma (paper V), and might hence be connected to more heavy inflammatory conditions of the lung, giving rise to symptoms like altered lung function and respiratory symptoms. A shift in the $MC_{TC}/MC_T$ balance suggests that the microenvironment promote growth of the $MC_{TC}$ population while the normally prevailing $MC_T$ cells are reduced. More work is now needed to further explore the potential processes involved in the shift in the proportion of mast cell populations in asthma, COPD, CF and IPF. Irrespective of underlying mechanism, a change in the $MC_{TC}/MC_T$ proportion is likely to have functional consequences and indeed, several correlations between multiple disease-related changes in density, balance of mast cell subtypes and lung function data were found. The expanded density of $MC_{TC}$ also correlated to the degree of fibrosis as well as density of collagen in the lungs of patients with CF and IPF.

**Effect of medication on mast cell subpopulations**

The on-going medication of the patients included in this thesis could have contributed to the shift in $MC_T/MC_{TC}$ balance. ICS have been demonstrated to reduce mast cell numbers in central airways \(^{170}\), and have been shown to mainly affect mucosal mast cells in various compartments of the respiratory system \(^{171-173}\). However, the baseline density of $MC_{TC}$ in some of these studies \(^{171 173}\) was low and it is difficult to draw any conclusion if ICS selectively affected only the $MC_T$ population. The results from the study of uncontrolled atopic asthma (paper IV) might indicate that ICS have an effect on mast cell subtype balance as a reduction of $MC_T$ but not $MC_{TC}$ was found in central airways. The fact that both subtypes expand in the alveolar parenchyma may show that the on-going ICS therapy did not reach this compartment. No changes in mast cell densities were observed in cases of mild asthma compared to healthy controls, and non of these patients were treated with ICS. The change in $MC_T/MC_{TC}$ balance seen in the COPD study might depend on ICS therapy, although decreased numbers of mast cells were observed already in moderate to severe COPD of which only one patient had ICS treatment (paper II). As one part of the changed mast cell subtype balance in the various investigated diseases depends on expansion in actual numbers of $MC_{TC}$, the altered balance is unlikely to solely be a ICS effect and should therefore be regarded as an important feature of COPD, CF and IPF pathology. When discussing potential drug effects on mast cells in non-allergic and allergic disease it should be noted that it is not entirely obvious whether anti-mast cell effects is solely beneficial. The potential effects of current and emerging drugs on lung mast cells should thus be explored with regard to both the destructive and pro-inflammatory capacity of mast cells as well as their potential beneficial role in innate immunity and host defence mechanisms.
Microenvironment and mast cell heterogeneity

Our discovery of site-specific mast cell subtypes under healthy conditions (paper I) supports the idea of microlocalisation as a determinant in creating differential phenotypes of infiltrating cells. Indeed, both the airways and pulmonary vessels contain sub-anatomical compartments such as smooth muscle bundles and epithelial/endothelial regions that may differentially attract mast cells and/or alter mast cell behaviour. Hence, the fact that pulmonary vessels, conducting airways and alveoli contain different proportions and types of structural cells may in part explain the present novel site-specific mast cell populations. Alterations in mast cell distribution in the airway wall have been described in asthma, with increases in mast cell numbers in the epithelial and smooth muscle layer. Infiltration of mast cells in specific airway layers in smokers with and without chronic bronchitis, and COPD has also been reported. This is likely to have several functional consequences. In our study we describe an increased proportion of both MC and MC in the inner layers (epithelium and lamina propria) of small airways in very severe COPD, a compartment where the mast cells are most likely to interact with for example pathogens and regulate an immune response as a response to an increased inflammatory process in these airway layers (paper II). In uncontrolled atopic asthma, we found an increase of MC in the smooth muscle layer compared to controls. This goes in line with previous studies, and further indicates that mast cell alterations are present in structures important for the disease pathology.

Mast cell expression patterns in health and disease

Apart from the classical staining for tryptase and chymase, the mast cells in paper I was assessed for expression of a variety of other mast cell-related molecules. By this approach we could demonstrate several statistically significant differences within each of the MC and MC subtypes, but also between the different compartments of the lung. The most interesting observation was the reduced expression of FcεRI and increased renin expression in the alveolar region, which will be further discussed below. Mast cells express numerous pro-inflammatory molecules and are traditionally considered to be part of harmful inflammatory processes. In paper II, the MC population in COPD displayed an increase in expression of the pro-fibrotic molecule TGF-β. As in COPD, the expanded MC population showed high expression of TGF-β in all compartments in lungs from patients with CF and IPF (paper III). The expression also correlated to the degree of fibrosis and patients lung function. The importance of TGF-β as a fibrotic agent in the lung has been widely demonstrated and an increased expression of TGF-β has been shown in tissue remodelling in CF and IPF. In mice and rat lungs a severe fibrotic response develops in the lung after induction of active TGF-β, when expressed in the airways stimulates fibroblasts to produce extracellular matrix proteins. This suggests important interactions between mast cells and fibroblasts, leading to remodelling and fibrosis and implicates that MC derived TGF-β plays an important role in this process. The anaphylatoxin receptor C5aR (CD88) was signifi-
cantly increased in all lung compartments in COPD (paper II). CD88 was used as a general marker of mast cell activation, and the increase indicates that the mast cells in COPD have acquired a more pro-inflammatory phenotype. IL-6 is a multifunctional regulator of immune and inflammatory processes and is a potent chemo-attractant for neutrophils. The pro-inflammatory cytokine IL-6 was selected as an indicator of an “inflammatory” mast cell phenotype in paper III. In CF lungs, both MC_{T} and MC_{TC} populations show elevated expression of IL-6 in all compartments investigated. The lower expression of IL-6 in IPF could indicate less active inflammation and lack of bacterial infections. Similarly, in CF the elevated IL-6 expression in less affected regions suggests that mast cell activation in this disease may take place early in the pathogenesis. In support of this, based on findings of increased lung mast cell numbers already in CF foetuses, it has been speculated that mast cells may participate even in the initiation of the inflammation and the lung histopathology changes seen in CF. However, the role of mast cells can be both pro- and anti-inflammatory. The MC_{TC} population had particularly high levels of renin in healthy conditions, a key hormone in vascular homeostasis recently identified in mast cells. Together with the capacity of chymase to act as an angiotensin converting enzyme and angiotensin II activator, this suggests a role for MC_{TC} in lung vascular regulation with potential implications in disease. Also histamine and serotonin have blood flow modulating capacities and this further underscores the potential of mast cells in vascular regulation of the lungs.

The role of alveolar mast cells in diseased lung

Previous studies have shown an increase in mast cell density in small airways compared to bronchi. Much less is known regarding mast cells in the alveolar compartment. Interestingly, in the studies in this thesis, the alveolar lung parenchyma was the most mast cell-rich compartment. Balzar et al. reported low levels of IgE-bearing mast cells in the alveolar tissue of asthmatics and healthy controls which suggests a reduced capacity for classical anaphylactic degranulation and IgE mediated activation among alveolar mast cells. It seems rational to have mechanisms for local down regulation of FcεRI and thus prevent an anaphylactic degranulation in the sensitive alveolar regions. Effects of classical degranulation like plasma extravasation would be a catastrophic event in the alveoli. The finding of low FcεRI expression on alveolar mast cells in healthy conditions is in agreement with previous reports. Alveolar mast cells might therefore under normal conditions be regulated by non-IgE mast cell triggers such as C5aR, CD30L etc. The finding of increased expression of FcεRI in the alveolar parenchyma in patients with mild and uncontrolled asthmatics (paper IV and V) was therefore surprising and intriguing. Since this phenomenon could not be found in non-allergic diseases (COPD, CF and IPF) as well as in AR, the FcεRI high expressing mast cell phenotype in alveolar parenchyma might be specific for asthma. Highly statistical increases of surface-bound IgE on mast cells in both central airways and the alveolar parenchyma were also demonstrated in mild and uncontrolled asthmatics. The consequences of IgE-mediated mast cell activation in the alveoli are however unknown, but from the known
range of pro-inflammatory effects caused by mast cell-derived mediators\textsuperscript{194-196}, these effects should be expected to be significant and multifaceted. Irrespective of activation mechanism, alveolar mast cells are likely to have a variety of roles ranging from regulation of blood flow, a notion supported by the present high renin content in alveolar mast cells, to participation in the many new functions recently ascribed to mast cells, ranging from immune modulators, effector cells in innate immunity to pro-fibrotic cells\textsuperscript{129 133 197 198} (see above).

A major prerequisite for induction of IgE-mediated alveolar mast cell activation is the possibility for allergens to reach the alveolar parenchyma. Although most of the inhaled allergens are deposited in the conducting airways, common allergens may well be transported by respirable particles all the way to the alveolar region\textsuperscript{199-201}. If high FcεRI and IgE-expressing alveolar mast cells are present in additional asthma cohorts needs to be further investigated. Anti-IgE therapy, Omalizumab (Xolair\textsuperscript{®}), was developed on the basis of the proposed IgE-driven allergic inflammation in the conducting airways\textsuperscript{202-204}. As expected, Omalizumab down-regulate both IgE and FcεRI-bearing mast cells in asthmatic bronchi\textsuperscript{18 19}. Future studies are now needed to investigate if anti-IgE therapy yields similar effects in the alveolar compartment.

**Study design: advantages and disadvantages**

The novel mast cell heterogeneity presented in this thesis has several practical implications. In agreement with previous studies\textsuperscript{14 76 92} this report shows that quantification of lung mast cells in disease without proper information of anatomical location or subtype may be misleading; a certain subtype in one location may display increased numbers and/or activation whereas the situation may be reversed in neighbouring areas. An additional aspect is the complexity in assessing lung-derived mast cells \textit{ex vivo}. From our data it can be expected that purification of mast cells from lung homogenates yield a mixture of several populations with potentially different propensity to survive and get activated \textit{ex vivo}. This type of heterogeneity may account for the many previously reported discrepancies in functionality among lung-derived mast cells. In this context knowledge about the present site-specific heterogeneity may be helpful if lung mast cells were instead purified from dissected well-defined compartments of the lung\textsuperscript{193}. In the majority of the studies included in this thesis we used large and multiple sections that contained all anatomical compartments from large patient groups (transplantation material and surgical resections). This made it possible to perform comparisons of mast cells, not only between health and disease, but also between compartments within each section. This also guaranteed that our comparison of mast cell parameters and molecular expression in the different anatomical regions was subjected to exactly the same immunohistochemical conditions. Lung tissue samples obtained during surgery for lung cancer are commonly used to assess lung diseases like COPD as well as collecting tissue from control subjects. Nevertheless this approach call for some cautiousness since the influence of cancer tumours on the neighbouring mast cells is hard to rule out. To minimize the risk of any influence of the cancer we only included patients with well-
delineated tumours and our samples were collected as far as possible from the tumour. To compensate for this uncertainty we also used a very unique tissue material, bronchial as well as transbronchial biopsies, from healthy young subjects without cancer diagnosis. This method was also used to study patients with mild and uncontrolled asthma and AR. To compensate for the small tissue volume obtained by this method multiple biopsies (>10 per patients) were taken.
Conclusions and Summary

The following conclusions can be drawn based on the results in this thesis:

• Extensive mast cell heterogeneity in the human lung is evident even at healthy baseline conditions. We conclude that the prevailing MC\textsubscript{T} and MC\textsubscript{TC} populations can be further divided into site-specific subpopulations dependent on the local microenvironment. Especially the alveolar mast cell population, with low expression of the high affinity receptor for IgE, stands out as a new hitherto unknown mast cell phenotype.

• Mast cell alterations are prominent features of non-allergic chronic inflammatory disorders of the lung. For example, in COPD, an increased proportion of MC\textsubscript{TC} with increased expression of pro-inflammatory mediators were found. Several mast cell alterations in COPD correlated to patient lung function values.

• In fibrotic lung diseases, such as CF and IPF, the density of MC\textsubscript{TC} was increased. This alteration, as well as mast cell expression of pro-fibrotic molecules, was particularly prominent in the remodelled alveolar parenchyma and correlated to patient lung function and to the degree of tissue fibrosis.

• Atopic asthma patients with persistent symptoms despite ICS therapy show expanded MC\textsubscript{T} and MC\textsubscript{TC} populations in the alveolar parenchyma. These populations have a significantly increased expression of Fc\varepsilon RI and surface-bound IgE. Apart from advancing the concept of a distal airway inflammation in asthma, this observation provides important indications regarding how to improve treatment strategies for uncontrolled asthma. The phenomenon of increased Fc\varepsilon RI expression on alveolar mast cells might be specific to atopic asthma since we could detect similar changes in mild asthma, but not in patients with allergic rhinitis, CF and COPD.
<table>
<thead>
<tr>
<th>Inflammatory respiratory disease</th>
<th>COPD n = 25</th>
<th>CF n = 5</th>
<th>IPF n = 7</th>
<th>Uncrtl. asthma n= 14</th>
<th>Mild asthma n = 8</th>
<th>Allergic rhinitis n = 8+8</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bronchi</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MC&lt;sub&gt;T&lt;/sub&gt;</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MC&lt;sub&gt;TC&lt;/sub&gt;</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expression pattern</td>
<td>FcεRI →</td>
<td>FcεRI →</td>
<td>FcεRI → IgE →</td>
<td>FcεRI → IgE →</td>
<td>IgE →</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TGF-β ↑</td>
<td>TGF-β ↑</td>
<td>TGF-β ↑ IL-6 ↑</td>
<td>TGF-β ↑ IL-6 ↑</td>
<td>IL-6 →</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CD88 ↑</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renin ↓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bronchioles</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MC&lt;sub&gt;T&lt;/sub&gt;</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MC&lt;sub&gt;TC&lt;/sub&gt;</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expression pattern</td>
<td>FcεRI →</td>
<td>FcεRI →</td>
<td>FcεRI → IgE →</td>
<td>FcεRI → IgE →</td>
<td>IgE →</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TGF-β ↑</td>
<td>TGF-β ↑</td>
<td>TGF-β ↑ IL-6 ↑</td>
<td>TGF-β ↑ IL-6 ↑</td>
<td>IL-6 →</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CD88 ↑</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renin ↓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Alveolar parenchyma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MC&lt;sub&gt;T&lt;/sub&gt;</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>→</td>
<td>→</td>
</tr>
<tr>
<td>MC&lt;sub&gt;TC&lt;/sub&gt;</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>→</td>
<td>→</td>
</tr>
<tr>
<td>Expression pattern</td>
<td>FcεRI →</td>
<td>FcεRI →</td>
<td>FcεRI → IgE →</td>
<td>FcεRI → IgE →</td>
<td>IgE →</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TGF-β ↑</td>
<td>TGF-β ↑</td>
<td>TGF-β ↑ IL-6 ↑</td>
<td>TGF-β ↑ IL-6 ↑</td>
<td>IL-6 →</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CD88 ↑</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renin ↓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pulmonary vessels</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MC&lt;sub&gt;T&lt;/sub&gt;</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MC&lt;sub&gt;TC&lt;/sub&gt;</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expression pattern</td>
<td>TGF-β ↑</td>
<td>TGF-β ↑</td>
<td>TGF-β ↑ IL-6 ↑</td>
<td>TGF-β ↑ IL-6 ↑</td>
<td>IL-6 →</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CD88 ↑</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renin ↓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

n = number of patients. Unctrl = uncontrolled according to ACT score.
Future Perspective

The present thesis shed light upon new roles for mast cells in inflammatory airway diseases as well as the importance of studying mast cells directly in human diseased lung tissue. The present work also underscores the fact that more research is needed to understand the true nature of human lung mast cell populations under disease-relevant \textit{in vivo} conditions. Indeed, the present thesis has identified some remaining fundamental questions that now await further investigations.

Biological and pathological roles of alveolar mast cells in health and disease

Today very little is known regarding the role of alveolar mast cells, in healthy conditions or in disease. Further characterisation of these cells is necessary, concerning heterogeneity, molecular expression patterns and function. Research needs to be done in finding the role and activation mechanisms for alveolar mast cells in healthy conditions. Means of studying alveolar mast cell function need to be investigated and evaluated in \textit{in vitro}, explant and animal models. Very little knowledge exists about the peripheral inflammation in asthma and the role of mast cells. Although the present thesis shows an altered alveolar mast cell phenotype, possibly activated by IgE, these mast cells need to be further characterised by their expression pattern of leukotrienes, prostaglandins and cytokines. Also analyses of the activation status of these cells (whole mount studies of activation and degranulation status on and of season) seem warranted. More knowledge about how to target the alveolar mast cell population with today’s available (or future) therapy is necessary. How anti-IgE treatment affects alveolar mast cells and the expression of Fc\varepsilonRI seems to be an important future research area.

The role of mast cells in airway infections

Chronic colonisation of bacteria and viruses are part of the pathological picture in both asthma, COPD and CF. To study how mast cell populations are affected by viruses in the human lung are important for understanding the role of mast cells in the above mentioned conditions. Through collaborations, we have access to tissue material from 22 children who have died from respiratory syncytial-, adeno- and influenza viral infections. The phenotype of these mast cells, with regard to expression of pro- and anti-inflammatory mediators as well as expression of toll-like receptors will be examined.
Translating \textit{in vitro} findings into \textit{in vivo} contexts

The finding of extensive mast cell heterogeneity in this thesis raises important questions regarding the possible translation of \textit{in vitro} findings into \textit{in vivo} settings. A future challenge is to find equivalents of mast cell lines in different human lung compartments in both healthy and diseased conditions.
Mastcellen är en cell som ingår i immunförsvaret och finns i hela kroppen men är speciellt många i organ som har kontakt med den yttre miljön, så som lungor, hud och mag-tarmkanal. Mastceller har länge varit förknippade med de skadliga effekter som observerats i allergiska överkänslighetsreaktioner, och mastceller kan producera och utsöndra ämnen som ger upphov till typiska allergisymptom vid luftvägsallergi så som andnöd, hosta, nysningar, klåda, svullnad och rinnsnuva. Mindre kunskap finns om vilken roll mastceller har i andra, icke-allergiska sjukdomar. Många av mastcellens ämnen ligger lagrade i ett stort antal kapslar inuti cellen och kan snabbt utsöndras när mastcellen aktiveras. Det finns, traditionellt sett, två olika subtyper av mastceller; slemhinnemastceller (MC\textsubscript{T}) och bindvävsmastceller (MC\textsubscript{TC}). Dessa subtyper skiljer sig åt i vilka ämnen de innehåller och i sin distribution i kroppen. Mastcellen är en evolutionärt sett en mycket gammal cell och eftersom de inte förändrats mycket genom evolutionen och finns i stort antal även hos friska människor tyder detta på en viktig roll i immunförsvaret. Mastceller av bindvävstypen har, exempelvis, påvisats hos sjöpung, ett djur som är 500 miljoner år äldre än människan, långt innan det specifika immunförsvaret utvecklades. Eftersom mastceller, till skillnad från många andra celler i immunförsvaret, endast mognar i vävnaden bestäms deras slutgiltiga egenskap (fentotyp) av den lokala vävnadsmiljön. Detta leder till att mastceller är mycket heterogena, vilket gör det svårt att studera dem. Mastcellpopulationerna skiljer sig också åt mellan djur och människa, bland annat saknar möss och råttor mastceller långt ut i lungan, ett område med mycket högt antal mastceller i människa.

I denna avhandling studeras därför mastcellernas lokalisering, heterogenitet och uttryck av ämnen endast i vävnad från människor som lider av olika allergiska och icke-allergiska lungsjukdomar. För att studera detta användes flera olika histologiska och immunohistokemiska metoder som utnyttjar cellens kemiska egenskaper eller antikroppar som känner igen specifika proteiner för att på tunna vävnadssnitt färga in mastceller. Bland annat studerades deras utseende (morfologi), vad de uttrycker för ämnen och receptorer samt den sjuka vävnaden i vilken de befinner sig i.

Eftersom mycket lite är känt om mastcellernas heterogenitet i friska lungor, studerades detta i delarbete I. Vi fann bland annat att mastcellpopulationen kan ytterligare delas in fler subtyper än MC\textsubscript{T} och MC\textsubscript{TC}, beroende på deras förekomst i små och stora luftvägar, lungans kärl samt lungblåsorna (alveolärt parenkym). Ett huvudfynd i denna studie var att den alveolära mastcellpopulationen skiljer sig markant från de övriga. Bland annat saknar denna typ av mastcell receptorn för IgE, en antikropp som aktiverar
mastcellen i allergiska reaktioner. Det innebär att i alveolärt parenkym kan mastcellen inte aktiveras av allergen, och måste således ha en annan funktion. I delarbete II studerades hur dessa nya mastcellspopulationer förändrades i samband med den inflammationsome som ses vid olika svårighetsgrader av kroniskt obstruktiv lungsjukdom (KOL) som orsakas av rökning. Vi fann att andelen bindvävsmastceller, som normalt är mycket få, ökar med ökad svårighetsgrad av KOL. Också mastcellernas uttryck av inflammatoriska ämnen ökade. I delarbete III studerades mastceller i två olika lungsjukdomar, som karakteriseras av massiv inlagring av bindväv i lungan. Också här ökade antalet bindvävsmastceller dramatiskt. Denna ökning sammanföll med graden av fibros i lungan, patienternas lungfunktion samt mastcellernas uttryck av ämnen viktiga för fibrosutvecklingen. Trots att allergisk astma är en av de vanligaste kroniska sjukdomarna vet man mycket lite om vad som händer i de perifera delarna av lungan samt vad som gör att en stor andel av patienterna inte svarar på dagens behandling. I delarbeten IV och V studerades därför de alveolära mastcellerna i patienter med mild och svårbehandlad astma och patienter med hösnuva. Huvudfyndet i dessa studier var att de alveolära mastcellerna, som normalt inte uttrycker IgE receptorn, uppvisar ett markant ökat uttryck av IgE receptorn hos patienter med mild och svårbehandlad astma, men inte hos patienter med allergisk hösnuva. Detta innebär att mastceller, som hos friska personer inte kan reagera ”allergiskt”, nu har den förmågan hos patienter med astma och det i ett område som normalt inte nås av dagens allergibehandling.

Slutsatserna i denna avhandling är att mastcellernas heterogenitet är utbredd redan hos friska människor. Denna heterogenitet är viktig att studera för att kunna förstå vad som händer i sjuka tillstånd. Mastcellerna är förändrade i icke-allergiska lungsjukdomar som KOL och lungfibros. Ett kännetecken för allergiska astmatiker, men inte allergiska patienter med hösnuva, är ett ökat uttryck av IgE receptorn i alveolärt parenkym, något som är potentiellt viktigt för behandlingen av denna patientgrupp. Sammantaget har denna avhandling identifierat en rad nya aspekter kring mastcellernas potentiella roll i friska lungor och i lungor från patienter med våra vanligaste luftvägssjukdomar. Denna nya kunskap kan förhoppningsvis stimulera till ny viktig forskning och i förlängningen bidra till förbättrad behandling vid alla de sjukdomar där mastcellerna tycks ha en betydande roll.
Acknowledgements

I wish to express my sincere gratitude to all who have contributed and supported me during my PhD studies. This thesis would not exist without the encouragement from numerous people, both inside and outside the lab. I would especially like to thank:

My main supervisor, Jonas Erjefält, for introducing and guiding me in the complex field of airway inflammation. For sharing your great scientific and practical knowledge and for your ability to look at things with fresh eyes, and for teaching me to see beyond what is known. Thank you for your invaluable support, and kindness, which have contributed to interesting and enjoyable years in your group. My co-supervisor, Leif Bjerner, for sharing your great clinical and pre-clinical knowledge. Thank you for your unlimited generosity and enthusiasm and for stimulating conversations and discussions. Thanks for letting me take part in the clinical research at the Dept. of Respiratory Medicine.

Karin Jansner, who has, from the very beginning, supported me with endless kindness and generosity. For patiently sharing your immense knowledge and experience in the field of histology. Karin, you have taught me everything I know in the lab, this thesis would not exist without you! Britt-Marie Nilsson, for your skilful experience in the field of electron microscopy and histology and for always being helpful, supportive and generous!

Present and former members of the Unit of Airway Inflammation: Michiko Mori, Beata Olejnicka, Anders Bergqvist, Gediminas Smailys and Chris van Hove for creating a good scientific environment and for interesting discussions. Kristina Rydell-Törmänen and Lena Uller, my colleagues and friends, for invaluable support and encouragement. Katarina Danielson for administrative support.

Ellen Tuftesson, my colleague and friend, for your endless scientific and personal support. Thanks for sharing your great clinical and pre-clinical knowledge, your honesty and for always finding the time to discuss and finding solutions. Claes-Göran Löfdahl, for sharing your excellent knowledge, and for your enthusiasm and encouragement. Gunilla Westergren-Thorsson and Anders Malmström for your passion for research, your kindness and for creating a good, stimulating scientific environment. Oskar Hermansson, for your support and for making every day in the lab enjoyable. Annika Andersson-Sjöland and Oskar Hallgren for your infinite encouragement and fun discussions. David Aronsson, for fun and stimulating discussions about science and life.

A sincere thanks to all who have been involved in the clinical studies. Louise Qvist, Anna Sikesjö, Mette Solum, Johan Olsson, Jonas Olsson in the ARINI study.
Magnus Dahlbäck, Leif Eriksson with collaborators in the transplantation team at AstraZeneca.

All collaborators at MedImmune for fruitful discussions regarding mast cell biology. 
Thanks to Thais Mauad, São Paulo University and Moises Selman and Annie Pardo, Mexico, for productive collaborations.

**Present and former members at BMC D12:** Maria, Kristian, Lizbet, Anna, Calle, Lena T, Marie, Anna-Karin, Sara, Emil, AnnKatrin, Angelica, Jenny, Irma, Yulie, Linnea, Yulia, Karl Swärd and group members, Bengt Olof Nilsson and group members, Per Hellstrand and group members, David Erlinge and group members, Roland Andersson and group members, Lo Persson, Ingemar Carlstedt, the veterinaries and everyone else at D12! Thank you for your support and for making my PhD studies enjoyable!

**Former members at BMC F10:** Eva Ekblad and group members, Frank Sundler and group members, Anna Themner-Persson and Doris Persson: Thank you for your support. Martin Nyström and LRI for making computers and technique function! Big thanks to Elin Sand, my ex-roomie for all your encouragement, being my only mast cell buddy in Lund, for taking good care of me when I was new and confused and for all late nights in the lab with the stereo at top volume!

**Members of the LURN Journal Club:** Thank you for all the scientific and perhaps less scientific discussions! Thanks to Pernilla Glader, Amelie Plymouth and Lisa Alemenyr.

**All members and participants at LURN:** Thanks for interesting meetings with excellent scientific presentations and discussions and for creating a cheerful atmosphere.

Sincere thanks to all participants and members of MacNet and its organiser Gunnar Nilsson, for creating excellent mast cell meetings with an enjoyable atmosphere.

All my friends for your support outside the lab. Without you I would have perished! To Katrin, Emma and Helena for your encouragement and all the funny moments, dinners and shopping sprees in Copenhagen. Emy for your endless support and for always making me laugh. Caroline, it has been invaluable to have someone who understands and to share this experience with. Catharina and Carolina, for making the University studies much more fun. Linn, who has been my close friend literally all my life.

**My relatives for your love and encouragement.** Till Clara och Ella för att ni alltid får mig att bli glad och till min morfar, Arvid, som är den klokaste person jag känner.

**My family for your endless support and unfailing love.** You have given me the confidence to start this journey and the strength to finish it. To my father, Per, for inspiring me to choose this path and for your guidance and support in difficult scientific situations. To my mother, Brita, for guiding and supporting me in everything that is not science and for always being there for me. To my brother, Mikael for constantly making me realise what is important in life.

*This study was supported by grants from the Heart and Lung Foundation, Sweden, the Swedish Medical Research Council, Swedish Asthma and Allergy Association's Research Foundation, the Crafoord Foundation and the Royal Physiographic Society in Lund.*
References


It is a capital mistake to theorise before one has data. Insensibly one begins to twist facts to suit theories, instead of theories to suit facts.

Sherlock Holmes
(Sir Arthur Conan Doyle)